STOCK TITAN

Terra Innovatum Q3 profit tops $61M on noncash gains

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Terra Innovatum Global N.V. (NKLR) reported net income of $61.027 million for the three months ended September 30, 2026, versus a $2.987 million loss a year earlier. Results primarily reflected noncash fair-value gains, including a $62.209 million gain on the share-settled contingent liability and a $5.262 million gain on warrant liabilities.

For the nine months, net income was $35.877 million versus a $5.580 million loss, while operating cash use was $19.626 million, compared with $3.688 million. Cash and equivalents were $82.372 million at September 30, 2026, with no outstanding borrowings. Management said cash and budgeted cash flows support operations for at least 12 months after November 16, 2026, and do not raise substantial doubt about continuing as a going concern.

The company has no operating revenue and is developing SOLO, an approximately 1 MWe micro-modular reactor. It has completed conceptual and detailed design and begun pre-application engagement with the U.S. Nuclear Regulatory Commission; its commercial deployment target is 2028. In October 2026, Terra announced a manufacturing program with ATB and Boldrocchi and component procurement for its first reactor, with no binding purchase commitments under those arrangements beyond those included in its commitments disclosure.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointQuarterly net income: $61.027 million, primarily from noncash fair-value gains.

Negative

  • Moderate pointNine-month operating cash use: $19.626 million, versus $3.688 million a year earlier.

Filing Explained

At September thirtieth, two milestone tranches could add forty million ordinary shares; two hundred seventy-four thousand seven hundred fifty sponsor shares remain unvested.

Form 10-Q is an unaudited quarterly report covering interim financial statements and updates to risks and liquidity. At September 30, 2026, two remaining preferred-share tranches, convertible into 40 million ordinary shares, had not met their milestones, and 274,750 sponsor shares remained unvested; the sponsor shares were already legally issued but excluded from the reported ordinary-share count.

The third and fourth tranches convert or vest upon the earlier of share-price targets of $16.00 and $18.00, respectively, or the related regulatory milestones, through October 9, 2032. If the 40 million ordinary shares are issued, the increased share count would reduce existing holders’ percentage ownership absent offsetting changes.

The filing reports 45,940,341 potential ordinary shares excluded from diluted earnings per share: 40,200,000 on preferred-share conversion, 5,465,591 on warrant exercise, and 274,750 unvested sponsor shares. The exclusion reflects unmet issuance or vesting conditions or anti-dilution treatment; it does not mean all those shares have been issued.

Separately, the company reported $4,302 thousand in remaining noncancelable engineering and development commitments, expected to be paid through December 31, 2027; $1,119 thousand would be payable if all remaining milestones are achieved.

Quarterly net income $61.027 million Three months ended September 30, 2026; compared with a $2.987 million loss in 2025.
Quarterly diluted earnings per ordinary share $0.55 per ordinary share Three months ended September 30, 2026; compared with a $0.06 loss per share in 2025.
Nine-month net income $35.877 million Nine months ended September 30, 2026; compared with a $5.580 million loss in 2025.
Net cash used in operating activities $19.626 million Nine months ended September 30, 2026; compared with $3.688 million in 2025.
Cash and cash equivalents $82.372 million As of September 30, 2026.
Gain from change in fair value of share-settled contingent liability $62.209 million Three months ended September 30, 2026.
Gain from change in fair value of warrant liabilities $5.262 million Three months ended September 30, 2026.
SOLO designed baseload power output Approximately 1 MWe Micro-modular nuclear reactor design.
share-settled contingent liability financial
"remaining third and fourth tranches remain classified as share-settled contingent liabilities"
Level 3 financial
"classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs"
Level 3 describes the lowest-confidence category in the accounting “fair value” hierarchy, covering assets or liabilities whose prices are not observable in the market and must be estimated using judgment and internal models. For investors, Level 3 items matter because they can introduce greater uncertainty and potential valuation swings—like valuing a unique antique versus checking a price tag on a supermarket shelf—so they signal higher model risk and lower liquidity.
anti-dilutive financial
"all such instruments were anti-dilutive and therefore excluded from diluted EPS"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.
pre-application engagement regulatory
"initiated pre-application engagement with the U.S. Nuclear Regulatory Commission"
MWe technical
"approximately 1 megawatt electric (“MWe”) of baseload power"
low enriched uranium technical
"utilizing commercially available low enriched uranium (“LEU”)"
Low enriched uranium is uranium that has been processed so the concentration of the fissile isotope (U‑235) is raised above natural levels but kept well below the concentration used for weapons. Investors care because it is the standard fuel for most commercial nuclear reactors and thus links to electricity supply, fuel prices, regulatory approvals and geopolitical risks; think of it as refined fuel oil for nuclear plants, whose availability and rules affect utility earnings and energy markets.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much net income did NKLR report in Q3 2026?

Terra Innovatum reported $61.027 million in net income for the three months ended September 30, 2026, compared with a $2.987 million net loss in the same period of 2025. The result primarily reflected noncash fair-value gains, including gains on share-settled contingent and warrant liabilities.

How much cash did NKLR have at September 30, 2026?

Terra Innovatum reported $82.372 million in cash and cash equivalents and no outstanding borrowings at September 30, 2026. Management said cash and budgeted cash flows support operations for at least 12 months after November 16, 2026, and concluded that the conditions did not raise substantial doubt about the company’s ability to continue as a going concern.

What is Terra Innovatum’s SOLO reactor deployment target?

Terra Innovatum targets commercial deployment of SOLO by 2028. The company said it had completed the conceptual and detailed design phases, validated certain key technological components, and initiated pre-application engagement with the U.S. Nuclear Regulatory Commission; regulatory and licensing activities for future construction and operation are ongoing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
P1Y 00-0000000 0002067627 false --12-31 Q3 http://fasb.org/srt/2026#ChiefExecutiveOfficerMember 1 0002067627 2026-07-01 2026-09-30 0002067627 us-gaap:SubsequentEventMember 2026-10-05 2026-10-05 0002067627 2026-01-01 2026-09-30 0002067627 2026-09-30 0002067627 2025-01-01 2025-09-30 0002067627 2025-07-01 2025-09-30 0002067627 us-gaap:RestrictedStockMember 2026-09-30 0002067627 nklr:SponsorMember 2026-09-30 0002067627 nklr:Equity-ClassifiedWarrantsMember 2026-09-30 0002067627 nklr:Liability-ClassifiedMember 2026-09-30 0002067627 2025-10-09 2025-10-09 0002067627 nklr:EngineeringAndDevelopmentAgreementsMember 2026-09-30 0002067627 2025-10-14 0002067627 nklr:CapitalMarketsAdvisoryAgreementsMember 2026-09-30 0002067627 nklr:CapitalMarketsAdvisoryAgreementsMember 2026-01-01 2026-09-30 0002067627 srt:MaximumMember 2026-01-01 2026-09-30 0002067627 nklr:InvestorRelationsAndAdvisoryServicesAgreementsMember 2026-01-01 2026-09-30 0002067627 nklr:LiabilityClassifiedConvertiblePreferredSharesMember 2026-09-30 0002067627 nklr:TwoThousandTwentyFiveEquityIncentivePlanMember 2026-01-01 2026-09-30 0002067627 us-gaap:CommonStockMember nklr:TwoThousandTwentyFiveEquityIncentivePlanMember 2026-01-01 2026-09-30 0002067627 nklr:TwoThousandTwentyFiveEquityIncentivePlanMember 2026-09-30 0002067627 nklr:TwoThousandTwentyFiveEquityIncentivePlanMember 2026-09-25 2026-09-25 0002067627 nklr:TwoThousandTwentyFiveEquityIncentivePlanMember 2026-09-22 2026-09-22 0002067627 nklr:TwoThousandTwentyFiveEquityIncentivePlanMember nklr:August312026Member 2026-09-22 2026-09-22 0002067627 nklr:TwoThousandTwentyFiveEquityIncentivePlanMember nklr:June302027Member 2026-09-22 2026-09-22 0002067627 nklr:SPACFinancialAdvisorPreferredSharesMember 2026-01-01 2026-09-30 0002067627 nklr:SPACFinancialAdvisorPreferredSharesMember 2026-09-30 0002067627 nklr:Equity-ClassifiedConvertiblePreferredSharesMember 2026-09-30 0002067627 nklr:ThirdAndFourthTranchesMember 2026-09-30 0002067627 nklr:ConvertiblePreferredSharesMember 2026-09-30 0002067627 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0002067627 nklr:VestingSponsorSharesMember us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2026-09-30 2026-09-30 0002067627 nklr:SponsorMember 2026-01-01 2026-09-30 0002067627 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2026-01-01 2026-09-30 0002067627 us-gaap:WarrantMember 2026-09-30 0002067627 nklr:BridgeLoanWarrantMember 2026-09-30 0002067627 nklr:PIPEWarrantMember 2026-09-30 0002067627 us-gaap:WarrantMember 2026-07-01 2026-09-30 0002067627 nklr:BridgeLoanWarrantMember 2026-07-01 2026-09-30 0002067627 nklr:PIPEWarrantMember 2026-07-01 2026-09-30 0002067627 us-gaap:WarrantMember 2026-06-30 0002067627 nklr:BridgeLoanWarrantMember 2026-06-30 0002067627 nklr:PIPEWarrantMember 2026-06-30 0002067627 us-gaap:WarrantMember 2026-04-01 2026-06-30 0002067627 nklr:BridgeLoanWarrantMember 2026-04-01 2026-06-30 0002067627 nklr:PIPEWarrantMember 2026-04-01 2026-06-30 0002067627 us-gaap:WarrantMember 2026-03-31 0002067627 nklr:BridgeLoanWarrantMember 2026-03-31 0002067627 nklr:PIPEWarrantMember 2026-03-31 0002067627 us-gaap:WarrantMember 2026-01-01 2026-03-31 0002067627 nklr:BridgeLoanWarrantMember 2026-01-01 2026-03-31 0002067627 nklr:PIPEWarrantMember 2026-01-01 2026-03-31 0002067627 us-gaap:WarrantMember 2025-12-31 0002067627 nklr:BridgeLoanWarrantMember 2025-12-31 0002067627 nklr:PIPEWarrantMember 2025-12-31 0002067627 nklr:Liability-ClassifiedWarrantsMember 2026-01-01 2026-09-30 0002067627 nklr:Liability-ClassifiedWarrantsMember 2026-09-30 0002067627 nklr:PriorBridgeArrangementsMember 2026-09-30 0002067627 nklr:PriorBridgeArrangementsMember 2026-01-01 2026-09-30 0002067627 nklr:BridgeLoanWarrantsMember nklr:PriorBridgeArrangementsMember 2026-09-30 0002067627 nklr:BridgeLoanWarrantsMember nklr:PriorBridgeArrangementsMember 2026-01-01 2026-09-30 0002067627 nklr:PIPEWarrantsMember nklr:PIPEFinancingMember 2026-09-30 0002067627 nklr:PIPEWarrantsMember nklr:PIPEFinancingMember 2026-01-01 2026-09-30 0002067627 nklr:PIPEWarrantsMember 2026-09-30 0002067627 nklr:PIPEWarrantsMember 2026-01-01 2026-09-30 0002067627 srt:MinimumMember 2026-01-01 2026-09-30 0002067627 nklr:AdvisorWarrantMember 2026-09-30 0002067627 nklr:AdvisorWarrantMember 2026-01-01 2026-09-30 0002067627 us-gaap:MeasurementInputExpectedDividendRateMember nklr:BridgeLoanWarrantMember srt:MaximumMember 2026-09-30 0002067627 us-gaap:MeasurementInputExpectedDividendRateMember nklr:BridgeLoanWarrantMember srt:MinimumMember 2026-09-30 0002067627 us-gaap:MeasurementInputExpectedDividendRateMember nklr:PIPEWarrantMember srt:MaximumMember 2026-09-30 0002067627 us-gaap:MeasurementInputExpectedDividendRateMember nklr:PIPEWarrantMember srt:MinimumMember 2026-09-30 0002067627 us-gaap:MeasurementInputRiskFreeInterestRateMember nklr:BridgeLoanWarrantMember srt:MaximumMember 2026-09-30 0002067627 us-gaap:MeasurementInputRiskFreeInterestRateMember nklr:BridgeLoanWarrantMember srt:MinimumMember 2026-09-30 0002067627 us-gaap:MeasurementInputRiskFreeInterestRateMember nklr:PIPEWarrantMember srt:MaximumMember 2026-09-30 0002067627 us-gaap:MeasurementInputRiskFreeInterestRateMember nklr:PIPEWarrantMember srt:MinimumMember 2026-09-30 0002067627 us-gaap:MeasurementInputPriceVolatilityMember nklr:BridgeLoanWarrantMember srt:MaximumMember 2026-09-30 0002067627 us-gaap:MeasurementInputPriceVolatilityMember nklr:BridgeLoanWarrantMember srt:MinimumMember 2026-09-30 0002067627 us-gaap:MeasurementInputPriceVolatilityMember nklr:PIPEWarrantMember srt:MaximumMember 2026-09-30 0002067627 us-gaap:MeasurementInputPriceVolatilityMember nklr:PIPEWarrantMember srt:MinimumMember 2026-09-30 0002067627 us-gaap:MeasurementInputExpectedTermMember nklr:BridgeLoanWarrantMember srt:MaximumMember 2026-09-30 0002067627 us-gaap:MeasurementInputExpectedTermMember nklr:BridgeLoanWarrantMember srt:MinimumMember 2026-09-30 0002067627 us-gaap:MeasurementInputExpectedTermMember nklr:PIPEWarrantMember srt:MaximumMember 2026-09-30 0002067627 us-gaap:MeasurementInputExpectedTermMember nklr:PIPEWarrantMember srt:MinimumMember 2026-09-30 0002067627 nklr:BridgeLoanWarrantMember us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2026-09-30 0002067627 nklr:BridgeLoanWarrantMember us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2026-09-30 0002067627 nklr:PIPEWarrantMember us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2026-09-30 0002067627 nklr:PIPEWarrantMember us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2026-09-30 0002067627 nklr:BridgeLoanWarrantMember us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2026-09-30 0002067627 nklr:BridgeLoanWarrantMember us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2026-09-30 0002067627 nklr:PIPEWarrantMember us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2026-09-30 0002067627 nklr:PIPEWarrantMember us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2026-09-30 0002067627 nklr:FourthTrancheMember 2026-01-01 2026-09-30 0002067627 nklr:ThirdTrancheMember 2026-01-01 2026-09-30 0002067627 nklr:FourthTrancheMember 2026-09-30 0002067627 nklr:ThirdTrancheMember 2026-09-30 0002067627 us-gaap:FairValueInputsLevel3Member 2026-09-30 0002067627 us-gaap:FairValueInputsLevel3Member 2026-07-01 2026-09-30 0002067627 us-gaap:FairValueInputsLevel3Member 2026-06-30 0002067627 us-gaap:FairValueInputsLevel3Member 2026-04-01 2026-06-30 0002067627 us-gaap:FairValueInputsLevel3Member 2026-03-31 0002067627 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0002067627 us-gaap:FairValueInputsLevel3Member 2025-12-31 0002067627 nklr:Share-BasedPaymentArrangementTrancheFourthMember 2026-01-01 2026-09-30 0002067627 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2026-01-01 2026-09-30 0002067627 nklr:Share-BasedPaymentArrangementTrancheFourthMember 2026-09-30 0002067627 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2026-09-30 0002067627 nklr:ConvertiblePreferredShareMember 2026-09-30 0002067627 us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0002067627 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0002067627 nklr:BridgeLoanWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0002067627 nklr:BridgeLoanWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0002067627 nklr:PIPEWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0002067627 nklr:PIPEWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0002067627 nklr:Share-settledContingentLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0002067627 nklr:Share-settledContingentLiabilityMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0002067627 us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0002067627 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0002067627 nklr:BridgeLoanWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0002067627 nklr:BridgeLoanWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0002067627 nklr:PIPEWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0002067627 nklr:PIPEWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0002067627 nklr:Share-settledContingentLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0002067627 nklr:Share-settledContingentLiabilityMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0002067627 2025-12-31 0002067627 2026-04-01 2026-06-30 0002067627 2026-01-02 0002067627 nklr:SoftwareMember 2026-09-30 0002067627 nklr:ComputerHardwareMember 2025-12-31 0002067627 nklr:ComputerHardwareMember 2026-09-30 0002067627 nklr:FPoliSolutionsLLCAgreementMember 2025-12-31 0002067627 nklr:FPoliSolutionsLLCAgreementMember 2026-09-30 0002067627 nklr:ConsultingServicesAgreementMember 2026-01-01 2026-09-30 0002067627 nklr:EngineeringServicesAgreementMember 2026-01-01 2026-09-30 0002067627 nklr:EngineeringServicesAgreementMember 2026-07-01 2026-09-30 0002067627 nklr:ConsultingServicesAgreementMember 2026-07-01 2026-09-30 0002067627 nklr:EngineeringServicesAgreementMember 2026-09-30 0002067627 nklr:EngineeringServicesAgreementMember nklr:NineMember 2025-12-31 0002067627 nklr:EngineeringServicesAgreementMember nklr:NineMember 2026-09-30 0002067627 nklr:EngineeringServicesAgreementMember 2025-01-01 2025-09-30 0002067627 nklr:EngineeringServicesAgreementMember 2025-07-01 2025-09-30 0002067627 nklr:EngineeringServicesAgreementMember 2026-09-19 2026-09-19 0002067627 nklr:EngineeringServicesAgreementMember 2026-07-11 2026-07-11 0002067627 nklr:EngineeringServicesAgreementMember nklr:NineMember 2026-07-01 2026-09-30 0002067627 nklr:EngineeringServicesAgreementMember 2026-04-01 2026-06-30 0002067627 2026-01-01 2026-03-31 0002067627 nklr:LeaseAgreementMember 2026-01-01 2026-09-30 0002067627 nklr:NineMember 2026-09-30 0002067627 2025-09-30 0002067627 2024-12-31 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0002067627 us-gaap:RetainedEarningsMember 2025-09-30 0002067627 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0002067627 us-gaap:CommonStockMember 2025-09-30 0002067627 nklr:CorporateCapitalMember 2025-09-30 0002067627 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0002067627 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0002067627 2025-06-30 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0002067627 us-gaap:RetainedEarningsMember 2025-06-30 0002067627 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0002067627 us-gaap:CommonStockMember 2025-06-30 0002067627 nklr:CorporateCapitalMember 2025-06-30 0002067627 2025-04-01 2025-06-30 0002067627 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0002067627 nklr:CorporateCapitalMember 2025-04-01 2025-06-30 0002067627 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0002067627 2025-03-31 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0002067627 us-gaap:RetainedEarningsMember 2025-03-31 0002067627 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0002067627 us-gaap:CommonStockMember 2025-03-31 0002067627 2025-01-01 2025-03-31 0002067627 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0002067627 us-gaap:RetainedEarningsMember 2024-12-31 0002067627 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0002067627 us-gaap:CommonStockMember 2024-12-31 0002067627 us-gaap:AdditionalPaidInCapitalMember srt:RestatementAdjustmentMember 2024-12-31 0002067627 us-gaap:CommonStockMember srt:RestatementAdjustmentMember 2024-12-31 0002067627 nklr:CorporateCapitalMember srt:RestatementAdjustmentMember 2024-12-31 0002067627 srt:ScenarioPreviouslyReportedMember 2024-12-31 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:ScenarioPreviouslyReportedMember 2024-12-31 0002067627 us-gaap:RetainedEarningsMember srt:ScenarioPreviouslyReportedMember 2024-12-31 0002067627 nklr:CorporateCapitalMember srt:ScenarioPreviouslyReportedMember 2024-12-31 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-09-30 0002067627 us-gaap:RetainedEarningsMember 2026-09-30 0002067627 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0002067627 us-gaap:CommonStockMember 2026-09-30 0002067627 nklr:ConvertiblePreferredSharesMember 2026-09-30 0002067627 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-07-01 2026-09-30 0002067627 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0002067627 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0002067627 2026-06-30 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0002067627 us-gaap:RetainedEarningsMember 2026-06-30 0002067627 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0002067627 us-gaap:CommonStockMember 2026-06-30 0002067627 nklr:ConvertiblePreferredSharesMember 2026-06-30 0002067627 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-01 2026-06-30 0002067627 2026-03-31 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0002067627 us-gaap:RetainedEarningsMember 2026-03-31 0002067627 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0002067627 us-gaap:CommonStockMember 2026-03-31 0002067627 nklr:ConvertiblePreferredSharesMember 2026-03-31 0002067627 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0002067627 us-gaap:RetainedEarningsMember 2025-12-31 0002067627 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0002067627 us-gaap:CommonStockMember 2025-12-31 0002067627 nklr:ConvertiblePreferredSharesMember 2025-12-31 0002067627 2026-11-13 0002067627 nklr:ConvertiblePreferredSharesMember srt:ScenarioPreviouslyReportedMember 2024-12-31 0002067627 us-gaap:CommonStockMember srt:ScenarioPreviouslyReportedMember 2024-12-31 0002067627 us-gaap:AdditionalPaidInCapitalMember srt:ScenarioPreviouslyReportedMember 2024-12-31 0002067627 nklr:CorporateCapitalMember 2026-09-30 0002067627 nklr:CorporateCapitalMember 2026-07-01 2026-09-30 0002067627 nklr:ConvertiblePreferredSharesMember 2026-07-01 2026-09-30 0002067627 nklr:ConvertiblePreferredSharesMember 2025-04-01 2025-06-30 0002067627 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0002067627 nklr:CorporateCapitalMember 2025-07-01 2025-09-30 0002067627 nklr:ConvertiblePreferredSharesMember 2025-07-01 2025-09-30 0002067627 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0002067627 2025-01-01 2025-12-31 0002067627 nklr:Share-settledContingentLiabilityMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2026-09-30 0002067627 nklr:Share-settledContingentLiabilityMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2026-09-30 0002067627 nklr:PIPEWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2026-09-30 0002067627 nklr:PIPEWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2026-09-30 0002067627 nklr:BridgeLoanWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2026-09-30 0002067627 nklr:BridgeLoanWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2026-09-30 0002067627 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2026-09-30 0002067627 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2026-09-30 0002067627 nklr:Share-settledContingentLiabilityMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0002067627 nklr:Share-settledContingentLiabilityMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0002067627 nklr:PIPEWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0002067627 nklr:PIPEWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0002067627 nklr:BridgeLoanWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0002067627 nklr:BridgeLoanWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0002067627 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0002067627 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0002067627 nklr:CorporateCapitalMember 2026-01-01 2026-03-31 0002067627 nklr:ConvertiblePreferredSharesMember 2026-01-01 2026-03-31 0002067627 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0002067627 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0002067627 nklr:CorporateCapitalMember 2026-04-01 2026-06-30 0002067627 nklr:ConvertiblePreferredSharesMember 2026-04-01 2026-06-30 0002067627 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0002067627 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0002067627 nklr:CorporateCapitalMember 2026-06-30 0002067627 nklr:ConvertiblePreferredSharesMember 2025-06-30 0002067627 nklr:CorporateCapitalMember 2025-12-31 0002067627 nklr:CorporateCapitalMember 2026-03-31 0002067627 nklr:SoftwareMember 2025-12-31 0002067627 nklr:CorporateCapitalMember 2025-03-31 0002067627 nklr:ConvertiblePreferredSharesMember 2025-03-31 0002067627 nklr:ConvertiblePreferredSharesMember 2025-09-30 0002067627 nklr:CorporateCapitalMember 2024-12-31 0002067627 nklr:ConvertiblePreferredSharesMember 2024-12-31 0002067627 nklr:ConvertiblePreferredSharesMember srt:RestatementAdjustmentMember 2024-12-31 0002067627 us-gaap:RetainedEarningsMember srt:RestatementAdjustmentMember 2024-12-31 0002067627 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:RestatementAdjustmentMember 2024-12-31 0002067627 srt:RestatementAdjustmentMember 2024-12-31 0002067627 nklr:CorporateCapitalMember 2025-01-01 2025-03-31 0002067627 nklr:ConvertiblePreferredSharesMember 2025-01-01 2025-03-31 0002067627 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0002067627 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 xbrli:shares iso4217:USD xbrli:pure iso4217:USD xbrli:shares iso4217:EUR iso4217:EUR xbrli:shares nklr:megawatts nklr:Segments

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to _________

 

Commission File Number: 001-42901

 

TERRA INNOVATUM GLOBAL N.V.

(Exact name of registrant as specified in its charter)

 

The Netherlands   N/A

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

 

Via Matteo Trenta 117, Lucca, Italy 55100

55100 LU

(Address of principal executive offices) (Zip Code)

 

+39 0583 55797

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Ordinary Shares, par value of €0.01 per share   NKLR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 13, 2026, there were a total of 110,559,045 ordinary shares of the registrant issued and outstanding.

 

 

  

 

 

 

TERRA INNOVATUM GLOBAL N.V.

 

INDEX

 

  Page
   
PART I. FINANCIAL INFORMATION
     
Item 1. Financial Statements: 1
  Unaudited Consolidated Balance Sheets 1
  Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss) 2
  Unaudited Consolidated Statements of Changes in Shareholders’ Deficit 3
  Unaudited Consolidated Statements of Cash Flows 4
  Notes to Unaudited Consolidated Financial Statements 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 19
Item 3. Quantitative and Qualitative Disclosures About Market Risk 26
Item 4. Controls and Procedures 26
     
PART II. OTHER INFORMATION 29
     
Item 1. Legal Proceedings
Item 1A. Risk Factors 29
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 29
Item 3. Defaults Upon Senior Securities 29
Item 4. Mine Safety Disclosures 29
Item 5. Other Information 29
Item 6. Exhibits 30
     
SIGNATURES 31

 

i

 

 

Special Note Regarding Forward-Looking Statements

 

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this Form 10-Q, other than statements of historical fact, are based on our management’s beliefs and assumptions and on information currently available to us. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

 

● our goals and strategies, including our ability to build and commercialize a micro-modular nuclear reactor;

 

● our future business development, financial condition and results of operations;

 

● expected changes in our revenue, costs or expenditures;

 

● growth of and competition trends in our industry;

 

● our expectations regarding demand for, and market acceptance of, our products;

 

● our expectations regarding our relationships with investors, institutional funding partners and other parties with whom we collaborate;

 

● fluctuations in general economic and business conditions in the markets in which we operate; and

 

● relevant government policies and regulations relating to our industry.

 

In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part I, Item 1A “Risk Factors” of our Annual Report filed on Form 10-K for the year ended December 31, 2025 and Part II, Item 1A “Risk Factors” of our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026, and elsewhere in this report. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

 

In addition, statements that “we believe,” “we expect,” “we anticipate” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

 

The forward-looking statements made in this report relate only to events or information as of the date on which the statements are made in this report. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason after the date of this report or to reflect the occurrence of unanticipated events.

 

You should read this report and the documents that we reference in this report and have filed as exhibits to this report with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. These forward-looking statements speak only as of the date of this report.

 

ii

 

 

PART I

 

ITEM 1. FINANCIAL STATEMENTS.

 

Terra Innovatum Global N.V.

 

Unaudited Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

    September 30,     December 31,  
    2026     2025  
Assets            
Current assets:            
Cash and cash equivalents   $ 82,372     $ 102,882  
Accounts receivable, net     -       4  
Prepaid expenses and other current assets     7,951       3,148  
Total current assets     90,323       106,034  
Equipment and software, net     1,032       102  
Operating lease right-of-use assets     369       -  
Total assets   $ 91,724     $ 106,136  
Liabilities and shareholders’ deficit                
Current liabilities:                
Accounts payable   $ 1,471     $ 1,150  
Operating lease liabilities, current     53       -  
Accrued expenses and other current liabilities     4,770       2,009  
Total current liabilities     6,294       3,159  
Share-settled contingent liability     134,811       186,323  
Warrant liabilities     5,320       10,236  
Operating lease liabilities, non-current     316       -  
Other non-current liabilities     48       8  
Total liabilities     146,789       199,726  
Commitments and contingencies (Note 11)                
Shareholders’ deficit:                
Convertible preferred shares, €100 par value; 8,040 shares authorized; 20 and 20 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     3,086       3,086  
Ordinary shares, €0.01 par value; 500,000,000 shares authorized; 110,280,315 and 110,226,198 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     1,282       1,281  
Additional paid-in capital     519,664       519,422  
Accumulated deficit     (571,399 )     (607,276 )
Accumulated other comprehensive loss     (7,698 )     (10,103 )
Total shareholders’ deficit     (55,065 )     (93,590 )
Total liabilities and shareholders’ deficit   $ 91,724     $ 106,136  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

1

 

 

Terra Innovatum Global N.V.

 

Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except share and per share amounts)

 

    For the Three Months Ended September 30,     For the Nine Months Ended September 30,  
    2026     2025     2026     2025  
Operating expenses:                        
General and administrative   $ 5,437     $ 2,135     $ 15,431     $ 5,655  
Development costs     1,657       155       4,376       244  
Total operating expenses     7,094       2,290       19,807       5,899  
Loss from operations     (7,094 )     (2,290 )     (19,807 )     (5,899 )
Other income (expenses):                                
Other income (expenses)     650       (697 )     4,620       (941 )
Change in fair value - share settled contingent liability     62,209       -       46,382       -  
Change in fair value - warrant liabilities     5,262       -       4,682       1,260  
Total other (expense) income, net     68,121       (697 )     55,684       319  
Income (loss) before income taxes     61,027       (2,987 )     35,877       (5,580 )
Provision for income taxes     -       -       -       -  
Net income (loss)   $ 61,027     $ (2,987 )   $ 35,877     $ (5,580 )
Other comprehensive income (loss):                                
Change in foreign currency translation adjustment     (840 )     (49 )     2,405       (32 )
Total comprehensive income (loss)   $ 60,187     $ (3,036 )   $ 38,282     $ (5,612 )
Net income (loss) per ordinary share - basic and diluted   $ 0.55     $ (0.06 )   $ 0.33     $ (0.12 )
Weighted-average ordinary shares outstanding - basic     110,231,553       47,500,000       110,228,003       47,500,000  
Weighted-average ordinary shares outstanding - diluted
    110,234,376       47,500,000       110,229,053       47,500,000  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

2

 

 

Terra Innovatum Global N.V.

 

Unaudited Consolidated Statements of Changes in Shareholders’ Deficit

For the Three and Nine Months Ended September 30, 2026 and 2025

 

(in thousands, except share amounts)

 

    Corporate    

Convertible

Preferred Shares

    Ordinary shares    

Additional

paid-in

    Accumulated     Accumulated
other comprehensive
   

Total

shareholders’

 
    capital     Shares     Amount     Shares     Amount     capital     deficit     loss     deficit  
Balance as of January 1, 2026   $ -       20     $ 3,086       110,226,198     $ 1,281     $ 519,422     $ (607,276 )   $ (10,103 )   $ (93,590 )
Foreign currency translation     -       -       -       -       -       -       -       2,004       2,004  
Net loss     -       -       -       -       -       -       (7,106 )     -       (7,106 )
Balance as of March 31, 2026   $ -       20     $ 3,086       110,226,198     $ 1,281     $ 519,422     $ (614,382 )   $ (8,099 )   $ (98,692 )
Foreign currency translation     -       -       -       -       -       -       -       1,241       1,241  
Net loss     -       -       -       -       -       -       (18,044 )     -       (18,044 )
Balance as of June 30, 2026   $ -       20     $ 3,086       110,226,198     $ 1,281     $ 519,422     $ (632,426 )   $ (6,858 )   $ (115,495 )
Stock-based compensation     -       -       -       -       -       243       -       -       243  
Ordinary shares issued upon vesting of restricted share awards     -       -       -       54,117       1       (1 )     -       -       -  
Foreign currency translation     -       -       -       -       -       -       -       (840 )     (840 )
Net income     -       -       -       -       -       -       61,027       -       61,027  
Balance as of September 30, 2026   $ -       20     $ 3,086       110,280,315     $ 1,282     $ 519,664     $ (571,399 )   $ (7,698 )   $ (55,065 )

 

    Corporate    

Convertible

Preferred Shares

    Ordinary shares    

Additional

paid-in 

    Accumulated    

Accumulated other comprehensive

income

   

Total

shareholders’

 
    capital     Shares     Amount     Shares     Amount     capital     deficit     (loss)     deficit  
Balance as of January 1, 2025, as previously reported   $ 3       -     $ -       -     $ -     $ -     $ (37 )   $ 2     $ (32 )
Retrospective application of the Business Combination     (3 )     -            -       47,500,000     $ 551       (548 )     -       -       -  
Adjusted balance as of January 1, 2025   $ -       -     $ -       47,500,000     $ 551     $ (548 )   $ (37 )   $ 2     $ (32 )
Foreign currency translation     -       -       -       -       -       -       -       6       6  
Net loss     -       -       -       -       -       -       (1,448 )     -       (1,448 )
Balance as of March 31, 2025   $ -       -     $ -       47,500,000     $ 551     $ (548 )   $ (1,485 )   $ 8     $ (1,474 )
Issuance of warrants, net     -       -       -       -       -       1,077       -       -       1,077  
Capital contributions     12       -       -       -       -       -       -       -       12  
Foreign currency translation     -       -       -       -       -       -       -       11       11  
Net loss     -       -       -       -       -       -       (1,145 )     -       (1,145 )
Balance as of June 30, 2025   $ 12       -     $ -       47,500,000     $ 551     $ 529     $ (2,630 )   $ 19     $ (1,519 )
Equity-classified warrants issued with Bridge Loans, net     -       -       -       -       -       325       -       -       325  
Foreign currency translation     -       -       -       -       -       -       -       (49 )     (49 )
Net loss     -       -       -       -       -       -       (2,987 )     -       (2,987 )
Balance as of September 30, 2025   $ 12       -     $ -       47,500,000     $ 551     $ 854     $ (5,617 )   $ (30 )   $ (4,230 )

  

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

3

 

 

Terra Innovatum Global N.V.

 

Unaudited Consolidated Statements of Cash Flows

(in thousands)

 

    For the Nine Months Ended September 30,  
    2026     2025  
Cash flows from operating activities                
Net income (loss)   $ 35,877     $ (5,580 )
Adjustments to reconcile net income (loss) to net cash used in operating activities:                
Unrealized foreign exchange loss (gain)     (2,934 )     15  
Change in fair value of warrants     (4,682 )     (1,260 )
Change in fair value of share-settled contingent liability     (46,382 )     -  
Interest expense - non-cash     -       646  
Depreciation and amortization expense     38       -  
Amortization of operating lease right-of-use asset     25       -  
Stock-based compensation     243       -  
Changes in operating assets and liabilities:                
Prepaid expenses and other current assets     (5,008 )     (290 )
Accounts receivable, net     4       -  
Accounts payable     367       2,439  
Accrued expenses and other current liabilities     2,810       245  
Operating lease liabilities     (25 )     -  
Other non-current liabilities     41       97  
Net cash used in operating activities     (19,626 )     (3,688 )
Cash flows from investing activities                
Purchases of equipment and software     (924 )     (94 )
Net cash used in investing activities     (924 )     (94 )
Cash flows from financing activities                
Proceeds from bridge loans     -       5,577  
Payment of debt issuance costs for Bridge Loans     -       (24 )
Capital contributions     -       11  
Proceeds from related party loans     -       195  
Net cash provided by financing activities     -       5,759  
Effect of exchange rate changes on cash and cash equivalents     40       105  
Net change in cash and cash equivalents     (20,510 )     2,082  
Cash and cash equivalents at beginning of the period     102,882       69  
Cash and cash equivalents at end of the period   $ 82,372     $ 2,151  
Supplemental disclosures of cash flow information:                
Cash paid for amounts included in the measurement of operating lease liabilities   $ 15     $ -  
Cash paid for income taxes   $ -     $ -  
Cash paid for interest   $ -     $ -  
Non-cash investing and financing activities:                
Operating lease right-of-use assets obtained in exchange for operating lease liabilities   $ 396     $ -  
Unpaid deferred transaction costs   $ -     $ 1,062  
Reclassification of liability-classified to equity-classified warrants   $ -     $ 193  
Fair value of warrant liability   $ -     $ 1,485  
Issuance costs allocated to Bridge Loans   $ -     $ 10  
Equity classified warrants in conjunction with Bridge Loans   $ -     $ 1,329  
Purchases of equipment included in accrued expenses   $ 67     $ -  

  

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

4

 


Terra Innovatum Global N.V.

 

Notes to the Unaudited Consolidated Financial Statements

(in thousands except share and per share amounts)

 

Note 1. Organization

 

Organization

 

Terra Innovatum Global N.V. (the “Company” or “Terra”) is a Dutch public limited liability company (naamloze vennootschap) organized under the laws of the Netherlands. The Company is registered in the Netherlands, and its legal headquarters is in Lucca, Italy, San Marco district at Via Matteo Trenta No. 117.

 

On October 9, 2025, the Company consummated a business combination with GSR III Acquisition Corp. (“GSR III”) (the “Merger”) pursuant to a Business Combination Agreement dated April 21, 2025, as amended (the “Business Combination”), which was accounted for as a recapitalization. Additional details are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. As a result of the Business Combination, the Company became a publicly traded parent company of the combined organization. The Company’s ordinary shares commenced trading on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “NKLR” on October 10, 2025.

 

Following the Business Combination, Terra Innovatum Srl. (“Legacy Terra”), the private operating company prior to the Business Combination, continues to operate as a wholly owned subsidiary of the Company.

 

Nature of Operations

 

The Company is developing a micro-modular nuclear reactor known as the SOLO™ Micro-Modular Nuclear Reactor (“SOLO”). The Company’s activities are currently centered on engineering design, technology validation, regulatory engagement, and supply chain planning related to the SOLO reactor. The SOLO reactor is designed to generate approximately 1 megawatt electric (“MWe”) of baseload power through a gas-cooled system utilizing commercially available low enriched uranium (“LEU”). The reactor design contemplates extended operating cycles, including refueling capabilities, subject to regulatory approval.

 

As of September 30, 2026, the Company has completed the conceptual and detailed design phases of SOLO and has validated certain key technological components. The Company has initiated pre-application engagement with the U.S. Nuclear Regulatory Commission (“NRC”) and is progressing through regulatory and licensing activities required for future construction and operation. The Company has not yet constructed a commercial reactor and has not generated revenue from operations. All activities to date relate to research and development and preparation for potential future commercialization.

 

Risks and Uncertainties

 

The Company is an early-stage nuclear energy technology company and has not generated revenue from its principal operations. The Company’s activities remain focused on research and development, regulatory engagement, and preparation for future commercialization of its SOLO reactor technology.

 

As of September 30, 2026, the Company is subject to risks and uncertainties common to early-stage development enterprises, including the ability to obtain required regulatory approvals, successfully advance its technology through the licensing process, and continue to access capital to fund operations and future commercialization efforts. The regulatory approval process for nuclear technologies is complex, time-consuming, and subject to factors beyond the Company’s control.

 

In addition, the Company will require substantial additional capital to complete development and achieve commercialization, and there can be no assurance that such financing will be available on acceptable terms, or at all.

 

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the account standards codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). The interim consolidated financial statements include the financial statements of Terra Innovatum Global N.V. and its subsidiaries. All intercompany balances and transactions have been eliminated.

 

5

 

 

The interim consolidated financial statements as of September 30, 2026 and for the three and nine months ended September 30, 2026 and 2025, in the opinion of management, include all adjustments, consisting of normal recurring items, to present fairly the Company’s financial position, results of operations, and cash flows. The Company’s operating results for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the full year. The interim consolidated financial statements and related notes as of and for the three and nine months ended September 30, 2026 have been prepared on the same basis as and should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2025, as reported in the Company’s 2025 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to the rules of the SEC. The Company believes the disclosures made are adequate to keep the information presented from being misleading.

 

Prior to the closing of the Business Combination, Legacy Terra completed a series of restructuring transactions (the “Terra Pre-Closing Reorganization”) to establish a holding company structure. The Terra Pre-Closing Reorganization was accounted for as a transaction between entities under common control in accordance with ASC 805-50. Accordingly, assets and liabilities were recorded at historical carrying amounts, and no goodwill, gain, or loss was recognized. As the reorganization resulted in a change in the reporting entity, the interim consolidated financial statements have been retrospectively adjusted to include the historical financial results of Legacy Terra, the Company’s predecessor, for all periods presented, as if the current corporate structure had been in effect since the earliest period presented.

 

Going Concern

 

In accordance with ASC 205-40, Presentation of Financial Statements—Going Concern, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The Company has not generated revenue, has incurred recurring losses from operations and negative cash flows from operating activities, including net cash used in operating activities of $19,626 for the nine months ended September 30, 2026, and expects to continue to incur operating losses as it advances the development and licensing of SOLO. As of September 30, 2026, the Company had cash and cash equivalents of $82,372 and no outstanding borrowings. Based on its cash and cash equivalents and its budgeted cash flows for the twelve months following November 16, 2026, the date these interim consolidated financial statements were issued, management has concluded that these conditions and events do not raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the interim consolidated financial statements are issued. Accordingly, the interim consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

 

Basis of Consolidation

 

The interim consolidated financial statements of the Company are presented in U.S. dollars and include the accounts of the Company and its wholly owned subsidiaries: Legacy Terra, an Italian limited liability company; Terra Innovatum Corp. (“TerraUS”), a Delaware corporation formed in December 2025, which began operations in April 2026; and XIT Corp. (formerly GSR III Acquisition Corp.), a Cayman Islands exempted company. All intercompany balances and transactions have been eliminated in consolidation.

 

The Company determines whether to consolidate an entity based on whether it has a controlling financial interest under ASC Topic 810, Consolidation (“ASC 810”). A controlling financial interest may be established through either (i) the variable interest entity (“VIE”) model or (ii) the voting interest entity (“VOE”) model.

 

Under the VIE model, an entity is considered a VIE if, among other factors, (i) the equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support, (ii) the equity holders lack the characteristics of a controlling financial interest, or (iii) voting rights are not substantive. The Company consolidates a VIE if it is the primary beneficiary, defined as the party that both (i) has the power to direct the activities that most significantly impact the entity’s economic performance and (ii) has the obligation to absorb losses or the right to receive benefits that could potentially be significant.

 

If an entity does not meet the definition of a VIE, the Company evaluates consolidation under the voting interest model. Under this model, the Company consolidates entities in which it has a controlling financial interest, generally evidenced by ownership of a majority of the voting interests. The Company has evaluated its legal entities under ASC 810-10-15-14 and determined that none meet the definition of a VIE. Accordingly, all such entities are considered VOEs, and the Company applies the voting interest model and consolidates its subsidiaries based on its controlling financial interest, which is evidenced by 100% ownership of the voting interests.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and disclosures of contingencies. Significant estimates include, but are not limited to, the fair value of share-settled contingent liabilities, equity-based compensation, warrant valuations, useful lives of long-lived assets, and deferred tax assets and related valuation allowances. Actual results may differ from those estimates.

 

6

 

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which approximates market value, because of the short maturity of these instruments. The Company maintains cash deposits with financial institutions that may exceed insured limits.

 

Equipment and Software

 

Equipment and software are stated at cost, net of accumulated depreciation and amortization. Equipment consists principally of computer equipment and servers and is depreciated using the straight-line method over an estimated useful life of five years, beginning when the asset is placed in service. Purchased software licenses for internal use are capitalized in accordance with ASC 350-40, Intangibles—Goodwill and Other—Internal-Use Software, and amortized using the straight-line method over five years from the date the software is placed in service. Software subscriptions and cloud computing (hosting) arrangements are expensed over the subscription term. Repairs and maintenance are expensed as incurred.

 

Fair Value Measurement

 

The Company measures certain financial assets and liabilities at fair value in accordance with ASC 820. Fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company uses a three-level hierarchy, which prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach and cost approach): Level 1 – quoted prices in active markets for identical instruments; Level 2 – quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and Level 3 – valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Financial assets and liabilities are classified in their entirety based on the most stringent level of input that is significant to the fair value measurement. The Company’s share-settled contingent liability and liability-classified warrants are measured using Level 3 inputs (see Note 8).

 

Foreign Currency Translation and Transaction Gains and Losses

 

The Company’s reporting currency is the United States Dollar (“$”), while its functional currency is the Euro (“€”), which it uses for conducting business and maintaining its books and records. The functional currency of Legacy Terra is also the euro. The functional currency of TerraUS and XIT Corp. is the U.S. dollar, the currency of the primary economic environment in which each operates; accordingly, their financial statements do not require translation. The accompanying interim consolidated financial statements are presented in US$.

 

Monetary assets and liabilities denominated in foreign currencies are remeasured at period-end exchange rates, and resulting foreign exchange gains and losses are recognized in earnings. For such monetary assets and liabilities that are measured at fair value, the Company has elected to present foreign exchange gains and losses arising from remeasurement within the same line item as the change in fair value of the underlying instruments in the interim consolidated statements of operations, as such amounts are considered an integral component of the overall fair value measurement. For other monetary assets and liabilities not measured at fair value, foreign exchange gains and losses are presented within other income (expense) in the interim consolidated statements of operations.

 

In accordance with ASC 830-30, Translation of Financial Statements, the Company and Legacy Terra translate their assets and liabilities from their functional currency into US$ using the exchange rate at the balance sheet date. Revenues and expenses are translated at the average exchange rate for the reporting period. Translation gains and losses are recorded as a separate component of accumulated other comprehensive income (“AOCI”) within the interim consolidated statements of changes in shareholders’ deficit.

 

Cash flows are translated at the average exchange rates for the reporting period. As a result, the amounts presented in the interim consolidated statements of cash flows may not directly reconcile with the corresponding changes in balances reported on the balance sheets.

 

During the three and nine months ended September 30, 2026, net foreign currency transaction gains recognized in the interim consolidated statements of operations and comprehensive income (loss), primarily from remeasurement of monetary assets and liabilities denominated in currencies other than the functional currency, totaled approximately $119 and $2,934, respectively, and are included in other income (expense).

 

Warrants and Derivative Instruments

 

The Company evaluates warrants and other equity-linked financial instruments, including contingently issuable warrants, under ASC 815-40, Derivatives and Hedging—Contracts in an Entity’s Own Equity, and ASC 480-10, Distinguishing Liabilities from Equity, to determine appropriate classification and subsequent measurement.

 

Instruments that meet the conditions for equity classification under ASC 815-40 (including being indexed to the Company’s own stock and requiring physical or net share settlement with no provisions that could require cash settlement outside the Company’s control) are classified in equity at issuance and are not subsequently remeasured.

 

Instruments that do not meet the equity-classification conditions under ASC 815-40 or that otherwise meet liability-classification criteria under ASC 480-10 are classified as liabilities. Such instruments are initially measured at fair value and subsequently remeasured at each reporting date, with changes in fair value recognized in earnings.

 

In accordance with ASC 815-40, equity-linked instruments that are contingently issuable, exercisable, or settleable are considered issued for accounting purposes when an enforceable contract or arrangement exists, regardless of whether the contingencies have been resolved. Accordingly, contingently issuable warrants entered into prior to the consummation of a business combination (including warrants issuable upon the completion of a de-SPAC transaction) are recognized prior to the de-SPAC, provided that the counterparty has delivered consideration or performed under the arrangement.

 

7

 

 

Contingently issuable warrants are evaluated at inception to determine whether they qualify for equity classification or represent liability-classified equity-linked instruments prior to resolution of the contingency. Liability-classified contingent warrants are initially measured at fair value on the issuance date and subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in earnings, until the contingency is resolved or equity classification becomes appropriate.

 

Upon resolution of a contingency for instruments that qualify for equity classification, any previously liability-classified warrants are reclassified to equity at their fair value on the resolution date and are not remeasured thereafter.

 

The Company also evaluates whether warrants or other equity-linked instruments contain foreign-currency-denominated exercise prices or other cross-currency features. Instruments that are not indexed to the Company’s functional currency, as determined under ASC 815-40, are classified as liabilities and measured at fair value, with changes recognized in earnings.

 

Share-settled Contingent Liabilities

 

The Company enters into arrangements that require settlement through the issuance of its ordinary shares upon the occurrence of specified contingent events. The Company evaluates such arrangements to determine the appropriate classification as either a liability or equity in accordance with ASC 480-10, Distinguishing Liabilities from Equity, and ASC 815-40, Contracts in Entity’s Own Equity. An obligation is classified as a liability when the arrangement requires settlement for a fixed or determinable monetary amount through the issuance of a variable number of shares or otherwise does not meet the criteria for equity classification.

 

Share-settled contingent liabilities are initially recorded at fair value and subsequently remeasured at fair value at each reporting date. Changes in fair value, together with foreign currency transaction gains and losses arising from the remeasurement of the liability into the functional currency (euro), are recognized in change in fair value – share settled contingent liability in the interim consolidated statements of operations and comprehensive income (loss). Translation adjustments arising from translating the liability from the functional currency into the reporting currency (U.S. dollar) are not recognized in earnings; they are recorded in other comprehensive income (loss) as part of the foreign currency translation adjustment, consistent with the Company’s foreign currency translation policy above, and are presented separately in the rollforward in Note 8. The liability is derecognized upon settlement or extinguishment of the underlying obligation.

 

The determination of fair value requires management judgment and the use of significant estimates, including assumptions regarding the expected term of the contingent obligation (i.e., the estimated period until the contingency is resolved or the award settles), the Company’s stock-price volatility over that expected term, the probability of achieving any relevant performance or market conditions, and appropriate discount rates. Expected term is based on the contractual term of the arrangement, adjusted as necessary for management’s expectations about the timing of settlement events.

 

Convertible Preferred Shares

 

Preferred shares that contain settlement features not solely indexed to the Company’s own stock, or that may require issuing a variable number of ordinary shares, are classified as liabilities and remeasured at fair value each period. Preferred shares that require or permit settlement solely in equity instruments and meet equity classification criteria are recorded in permanent equity.

 

Equity-Based Compensation

 

The Company accounts for equity-based awards granted to employees, directors, and nonemployees in accordance with ASC 718, Compensation—Stock Compensation. Equity-based awards are measured at their grant-date fair value and recognized as compensation cost over the requisite service period (or, for nonemployee awards, over the period in which the related goods or services are provided). The grant-date fair value of restricted share awards is based on the closing price of the Company’s ordinary shares on Nasdaq. Awards with service conditions are recognized using either a straight-line or graded vesting attribution method, based on the terms of the award. The Company accounts for forfeitures as they occur.

 

Related Party Transactions

 

Transactions with related parties are measured at the exchange amount, which is the amount established and agreed to by the related parties. The Company discloses material related-party transactions, including loans, engineering agreements, leases, and service arrangements. Related-party transactions are reviewed by management for reasonableness; however, such transactions may not be conducted at terms equivalent to those that prevail in arm’s-length transactions.

 

Income Taxes

 

The Company is domiciled in the Netherlands; however, the Company and Legacy Terra are subject to taxation under Italian tax laws. TerraUS, which began operations in April 2026, is subject to U.S. federal and state income taxes. TerraUS has incurred losses since it began operations, and no U.S. current income tax expense has been recognized for the three and nine months ended September 30, 2026. A full valuation allowance has been recorded against TerraUS’s net deferred tax assets.

 

8

 

 

The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Management believes that it is more likely than not that all deferred tax assets will not be realized.

 

The Company recognizes liabilities for potential tax payments to various tax authorities related to uncertain tax positions. The liabilities are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions, if any, are recorded as components of income tax expense.

 

The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the financial statements.

 

Reclassifications

 

Certain prior period amounts in the notes to the interim consolidated financial statements have been reclassified to conform to the current period presentation, including the categories presented within prepaid expenses and other current assets (Note 4) and accrued expenses and other current liabilities (Note 7). These reclassifications had no effect on previously reported total assets, total liabilities, net loss, shareholders’ deficit or cash flows.

 

Out-of-Period Adjustment

 

The operating expenses of TerraUS for April through June 2026, approximately $800, were not included in the Company’s interim consolidated financial statements for the three and six months ended June 30, 2026, which included only TerraUS’s cash and the related capital contribution. These expenses were recorded in the three months ended September 30, 2026. As a result, general and administrative expenses and development costs for the three months ended September 30, 2026 include approximately $800 that relates to the three months ended June 30, 2026; the amounts for the nine months ended September 30, 2026 are not affected. Management evaluated the out-of-period adjustment, both quantitatively and qualitatively, and concluded that it is not material to the interim consolidated financial statements for any period presented or to the previously issued interim consolidated financial statements.

 

Recent Accounting Pronouncements

 

In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. Subsequently, in January 2025, the FASB issued ASU No. 2025-01 to clarify the effective date of this guidance. ASU 2024-03 requires enhanced disclosure regarding specific expense categories, such as inventory costs, employee compensation, and depreciation, within the notes to the financial statements. The pronouncement is effective for annual reporting periods in fiscal years beginning after December 15, 2026, and for interim reporting periods beginning after December 15, 2027, with early adoption permitted. The guidance allows for either prospective or retrospective application. The Company does not expect the adoption of this pronouncement to have a material impact to its consolidated financial statements.

 

In September 2025, the FASB issued ASU No. 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivative Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract (ASU 2025-07), which refines the scope of Topic 815 by clarifying which contracts are subject to derivative accounting and expands the scope exception for certain contracts not traded on an exchange to include contracts for which settlement is based on operations or activities specific to one of the parties to the contract. The guidance also provides clarification under Topic 606 for share-based payments from a customer in a revenue contract. The guidance is effective for annual periods beginning after December 15, 2026 and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this pronouncement, if any.

 

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disaggregated information about the effective tax rate reconciliation and income taxes paid. As an emerging growth company that has elected to use the effective dates applicable to private companies, the Company will adopt ASU 2023-09 for the annual period beginning January 1, 2026, beginning with its Annual Report on Form 10-K for the year ending December 31, 2026. The guidance affects disclosures only and will not affect the Company’s financial position, results of operations or cash flows.

 

In September 2025, the FASB issued ASU No. 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which removes references to software development project stages and requires capitalization of software costs once management has authorized and committed to funding the project and it is probable that the project will be completed and the software will be used as intended. The guidance is effective for annual periods beginning after December 15, 2027, and interim periods within those annual periods, with early adoption permitted. The Company’s capitalized software consists of purchased licenses (Note 5), and the Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.

 

9

 

 

Note 3. Related Party Transactions

 

Lease Agreement

 

On April 1, 2025, the Company entered into a lease agreement with Nine Nuclear and Industrial Engineering S.R.L. (“Nine”), a related party because Alessandro Petruzzi, the Company’s Chief Executive Officer and a director, and Marco Cherubini, the Company’s Chief Technology Officer, serve as chairman and deputy chairman of Nine’s board of directors and own NineNG S.r.l., which holds 90% of Nine’s share capital, to sublease three office rooms from a property unit located in Lucca, Sorbano del Giudice, Via della Chiesa XXXII n. 759. The three office rooms will be used exclusively for professional office purposes and related activities. The term of the lease agreement is 24 months starting from April 1, 2025 and ending on March 31, 2027. Each party may withdraw from the lease agreement at any time before the expiration date of the contract, upon at least 30 days’ notice, without any penalty. Because either party may terminate the sublease at any time without penalty, the arrangement does not create enforceable rights and obligations beyond the notice period and is accounted for as a short-term lease. Accordingly, no right-of-use asset or lease liability has been recognized, and the rent is expensed as incurred. This sublease is separate from the Company’s office lease described in Note 6. The rent is $12 (€11) per annum, $1 (€1) monthly and an immaterial monthly fee as a flat-rate reimbursement for utilities and cleaning costs (the “Lease Fee”), with the total monthly amount to be paid no later than the 10th of each month. The Lease Fee will be updated annually by 75% of the variation in the official consumer price indices for worker and employee families as determined by the Italian National Institute of Statistics (“ISTAT”) in the previous year and subsequently year by year, with the first update taking effect on April 1, 2026. During the three and nine months ended September 30, 2026, the Company incurred $5 and $11 of rent and related utility charges, respectively, including the June 2026 rent, which was invoiced and recorded in July 2026. The Company paid $3 and $7 in rent to Nine during the three and nine months ended September 30, 2025, respectively.

 

Engineering Services Agreements

 

During 2026, the Company had three engineering services agreements with Nine, a related party, to support the design of the SOLO project: OFS25-41 (€433, covering December 2025 through March 2026), OFS26-16 (€190, covering April through June 2026) and OFS34-26 (€442, covering services from July 2026). Engineering services costs from Nine were $257 and $854 for the three and nine months ended September 30, 2026, respectively, and are included in development costs. Engineering services costs from Nine under its July 11, 2025 agreement (OFS25-03; €184) and its September 19, 2025 agreement (OFS25-09; €340) were $388 (€347) for both the three and nine months ended September 30, 2025. As of September 30, 2026, $84 was payable to Nine (none as of December 31, 2025) and included in legal, accounting and other professional services within accrued expenses and other current liabilities (Note 7), and the remaining commitment under OFS34-26 was €221 ($251).

 

Consulting Services Agreement

 

FPoliSolutions LLC (“FPoli”), an entity affiliated with Cesare Frepoli, a director and significant shareholder of the Company, provides nuclear safety and licensing consulting services to the Company. During the three and nine months ended September 30, 2026, the Company incurred $393 and $613, respectively, of consulting fees and reimbursable expenses from FPoli, primarily included in development costs. During the three and nine months ended September 30, 2025, the Company incurred $90 under an engineering services agreement with FPoli entered into on July 23, 2025, for work completed in September 2025, which is included in general and administrative expenses. TerraUS has a consulting agreement with FPoli dated April 23, 2026. Under an amendment signed on October 5, 2026 and effective August 1, 2026, the term was extended through December 31, 2026 at a fixed fee of $358 for the five-month period (approximately $72 per month). As of September 30, 2026, $143 was payable to FPoli ($72 (€61) as of December 31, 2025, payable by Legacy Terra for its 2025 services and paid in January 2026) and included in legal, accounting and other professional services within accrued expenses and other current liabilities (Note 7).

 

Loans from Former Quotaholders

 

During the nine months ended September 30, 2025, the Company received $195 under interest-free loan agreements entered into in 2024 and on March 21, 2025 with its then quotaholders, which were scheduled to mature on December 31, 2040. No amounts were outstanding under these agreements as of September 30, 2026 or December 31, 2025.

 

Note 4. Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets consisted of the following:

 

    September 30,     December 31,  
    2026     2025  
Value added tax receivable   $ 2,979     $ 1,030  
Advances to suppliers     2,590       -  
Bank interest receivable     1,175       375  
Income tax receivables     558       133  
Prepaid insurance     251       300  
Prepaid expenses and retainers     359       1,281  
Deposits and other     39       29  
Total prepaid expenses and other current assets   $ 7,951     $ 3,148  

 

10

 

 

Advances to suppliers represent payments made in advance to third-party engineering and component suppliers under SOLO development agreements. Advances are recognized in development costs as the related services are performed or contractual milestones are achieved.

 

Certain December 31, 2025 amounts have been reclassified to conform to the current period presentation: value added tax credits of $623 previously presented within tax receivables are presented within value added tax receivable; advisory fees, technical consultancy, membership fees, advertising and certain other prepaid amounts previously presented separately, together with $697 previously presented within insurance, are presented within prepaid expenses and retainers; and deposits previously included in other are presented within deposits and other. Total prepaid expenses and other current assets as of December 31, 2025 are unchanged. See Note 2.

 

Note 5. Equipment and software, net

 

Equipment and software, net consisted of the following:

 

    September 30,     December 31,  
    2026     2025  
Computer equipment   $ 785     $ 113  
Software     295       -  
Equipment and software, gross     1,080       113  
Less: accumulated depreciation and amortization     (48 )     (11 )
Equipment and software, net   $ 1,032     $ 102  

 

Depreciation and amortization expense for equipment and software was $23 and $38 during the three and nine months ended September 30, 2026, respectively. Depreciation expense for the three and nine months ended September 30, 2025 was not material.

 

Note 6. Leases

 

Lease Agreement

On January 2, 2026, the Company entered into a lease for office space in Lucca, Italy, with a noncancelable term commencing April 1, 2026 and expiring March 31, 2032. The lease provides for annual base rent of approximately $85 (€75), which is adjusted annually in accordance with the variation in the consumer price index published by the Italian National Institute of Statistics (“ISTAT”), as required under Italian commercial lease law. These index-based rent adjustments are variable lease payments and are recognized as expense in the period incurred; they are not included in the measurement of the lease liability or right-of-use asset.

 

The Company determines whether an arrangement contains a lease at inception and records a right-of-use (“ROU”) asset and lease liability for leases with terms greater than twelve months. The Company also subleases office space in Lucca from Nine, a related party, under an arrangement that either party may terminate upon at least 30 days’ notice without penalty; that arrangement is accounted for as a short-term lease and is not included in the amounts below. See Note 3.

 

Operating lease cost was $— and $22 during the three and nine months ended September 30, 2026, respectively, net of $22 (€19) of rent for April through June 2026 that the landlord waived in September 2026 because the premises were not fully available for use. The waiver was accounted for as a reduction of lease cost in the period in which it was granted. Straight-line lease cost before the waiver was $44 for the nine months ended September 30, 2026, including $25 of amortization of the right-of-use asset. The $25 decrease in operating lease liabilities exceeds the cash paid because it also reflects the waived April through June 2026 payments and the September 2026 payment, which was unpaid as of September 30, 2026. The cash paid for amounts included in the measurement of operating lease liabilities was $15 and $15 during the three and nine months ended September 30, 2026, respectively. The weighted average remaining lease term was 5.5 years, and the weighted-average discount rate was 9.22% as of September 30, 2026.

 

Future lease payments under operating leases as of September 30, 2026, were as follows:

 

    September 30,
2026
 
2026 (remaining)   $ 21  
2027     85  
2028     85  
2029     85  
2030     85  
Thereafter     106  
Total lease payments     467  
Less: imputed interest     (98 )
Present value of lease liabilities   $ 369  

 

11

 

 

Note 7. Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consisted of the following:

 

    September 30,     December 31,  
    2026     2025  
Legal, accounting and other professional services   $ 3,071     $ 1,202  
Value added tax payable     1,288       315  
Directors’ compensation     143       305  
Payroll and withholdings     260       152  
Other     8       35  
Total accrued expenses and other current liabilities   $ 4,770     $ 2,009  

 

Certain December 31, 2025 amounts have been reclassified to conform to the current period presentation: technical consultancy of $238, previously presented separately, is included in legal, accounting and other professional services; $177 previously included in wages payable is presented within directors’ compensation; and the remaining wages payable are presented as payroll and withholdings. Total accrued expenses and other current liabilities as of December 31, 2025 are unchanged. See Note 2.

 

Note 8. Fair Value Measurements

 

Financial Instruments Not Recorded at Fair Value

 

Due to their short-term nature, the carrying value of the Company’s cash and cash equivalents, prepaid expenses and other current assets, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate fair value.

 

Financial Instruments Recorded at Fair Value on a Recurring Basis

 

The following table presents the Company’s financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:

 

    Level 1     Level 2      Level 3       Total  
As of September 30, 2026:                        
Share-settled contingent liability     -       -       134,811       134,811  
PIPE Warrants     -       -       3,392       3,392  
Bridge Loan Warrants     -       -       1,928       1,928  
Total liabilities at fair value   $ -     $ -     $ 140,131     $ 140,131  
As of December 31, 2025:                                
Share-settled contingent liability     -       -       186,323       186,323  
PIPE Warrants     -       -       5,931       5,931  
Bridge Loan Warrants              -               -       4,305       4,305  
Total liabilities at fair value   $ -     $ -     $ 196,559     $ 196,559  

  

The Company had no financial assets measured at fair value on a recurring basis as of September 30, 2026 or December 31, 2025.

 

Share-settled Contingent Liability

 

At the consummation of the Business Combination on October 9, 2025 (“Closing”), the Company entered into share-settled arrangements involving (i) contingently Convertible Preferred Shares issued to former Terra Innovatum Global Srl. quotaholders and (ii) contingently vesting GSR III Sponsor LLC (“Sponsor”) ordinary shares subject to market-based and regulatory milestones. These arrangements may result in the issuance or vesting of a variable number of ordinary shares and are not solely indexed to the Company’s stock price. As a result, they were initially classified and measured as liabilities at fair value, with the related amounts recorded within share-settled contingent liability in the consolidated balance sheet.

 

On October 16, 2025, certain milestones were achieved, resulting in the settlement of a portion of these arrangements. Immediately prior to settlement, the corresponding share-settled contingent liability was remeasured to fair value. Upon settlement, the related liability was reclassified to equity.

 

12

 

 

As of September 30, 2026, unearned milestone tranches remain classified as share-settled contingent liabilities and are remeasured at fair value at each reporting date, with changes recognized in earnings until the applicable milestones are achieved or expire. The remaining third and fourth tranches (each consisting of 2,000 Convertible Preferred Shares, convertible into 20,000,000 ordinary shares, and 137,375 Sponsor shares) vest or convert upon the earlier of the Company’s share price reaching $16.00 and $18.00, respectively, or the docketing of the SOLO test reactor permit application and the receipt of the SOLO test reactor operating license, respectively, through October 9, 2032. Management estimates the probability of achieving these regulatory milestones at approximately 89% and 80%, with expected achievement dates of June to October 2027 and December 2027 to March 2028, respectively. The 20 equity-classified SPAC financial advisor preferred shares described in Note 10 are subject to the same conversion terms but are not remeasured.

 

The following tables provide a summary of changes in the estimated fair value of the Share-Settled Contingent Liability using significant Level 3 inputs:

 

Share-Settled Contingent Liability (Level 3)      
       
Balance as of January 1, 2026   $ 186,323  
Loss recognized in earnings due to change of fair value, including foreign currency remeasurement impact     3,335  
Foreign currency translation     (3,798 )
Balance as of March 31, 2026     185,860  
Loss recognized in earnings due to change of fair value, including foreign currency remeasurement impact     12,492  
Foreign currency translation     (1,825 )
Balance as of June 30, 2026     196,527  
Gain recognized in earnings due to change of fair value, including foreign currency remeasurement impact     (62,209 )
Foreign currency translation     493  
Balance as of September 30, 2026   $ 134,811  

  

The Company estimated the fair value of the Share-Settled Contingent Liability using a Monte Carlo simulation model. Future share price paths are simulated to estimate the probability and timing of achieving the remaining share price targets, and management’s estimates of the probability and timing of achieving the remaining regulatory milestones are applied. Each remaining tranche vests or converts upon the earlier of the applicable share price target or regulatory milestone. The significant inputs as of September 30, 2026 were as follows:

 

    As of September 30, 2026  
    Third tranche     Fourth tranche  
Share price   $ 3.39     $ 3.39  
Remaining contractual term (years)     6.0       6.0  
Weighted average expected volatility     105.0 %     105.0 %
Risk-free interest rate     5.08 %     5.08 %
Dividend yield     0.0 %     0.0 %
Probability of achieving regulatory milestones     89.3 %     80.4 %
Expected timing of regulatory milestone achievement (years)     0.75       1.25  

 

The fair value measurement of the Share-settled Contingent Liability is classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. The valuation is sensitive to changes in expected volatility and the probability-weighted outcomes associated with achieving the applicable market-based and regulatory milestones, such that increases in these assumptions would generally result in a higher fair value measurement and decreases would result in a lower fair value measurement. The probability and expected timing of achieving the regulatory milestones are significant unobservable inputs and are presented in the table above. Certain unobservable inputs are interrelated, and changes in one assumption may magnify or mitigate the effects of changes in other assumptions. Changes in these unobservable inputs are subject to estimation uncertainty, and reasonably different assumptions could have resulted in a materially different fair value measurement at the reporting date.

 

13

 

 

Liability Classified Warrants

 

The warrants issued to the PIPE Investor and Bridge Loan lenders in connection with the Merger are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities in the consolidated balance sheets. Warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the interim consolidated statements of operations and comprehensive income (loss).

 

The fair value of the PIPE Warrants, which are subject to redemption provisions, is estimated using a Monte Carlo simulation model, which considers the probability-weighted outcomes of future share price paths. The fair value of the Bridge Loan Warrants is estimated using the Black-Scholes option pricing model. Significant inputs used in the valuation include the Company’s share price at the valuation date, expected share price volatility, risk-free interest rate, expected term of the warrants, and expected dividend yield.

 

Because the valuation relies on significant unobservable inputs, the liability-classified warrants are classified within Level 3 of the fair value hierarchy.

 

The valuation of the liability-classified warrants is sensitive to changes in key unobservable inputs, particularly expected share price volatility and the probability-weighted outcomes of future share price paths. Increases in expected volatility would generally result in a higher fair value measurement, while decreases would result in a lower fair value. Additionally, changes in assumptions regarding the Company’s expected share price performance could materially affect the estimated fair value. Although management believes the assumptions used are reasonable and consistent with available market information, different assumptions could have resulted in a materially different fair value measurement at the reporting date.

 

The following table summarizes the significant assumptions used in the valuation of the liability-classified warrants as of September 30, 2026:

 

    As of September 30, 2026  
    PIPE Warrants     Bridge Loan Warrants  
Exercise price   $ 12.00     $ 16.00     $ 11.50     $ 15.00  
Share price   $ 3.39     $ 3.39     $ 3.39     $ 3.39  
Remaining contractual term (years)     4.03       4.03       2.03       2.03  
Weighted average expected volatility     104.0 %     104.0 %     117.0 %     117.0 %
Risk-free interest rate     4.92 %     4.92 %     4.77 %     4.77 %
Dividend yield     0.0 %     0.0 %     0.0 %     0.0 %

 

During the periods presented, there were no transfers between levels of the fair value hierarchy.

 

Note 9. Warrants

 

Equity-Classified Warrants

 

In connection with the Business Combination, the Company issued warrants to a financial advisor to purchase up to 1,000,000 ordinary shares at an exercise price of $7.00 per share. The warrants are exercisable for a term of five years and are classified as equity. These warrants were issued in exchange for advisory services and accounted for as share-based compensation under ASC 718.

 

Liability-Classified Warrants

 

The Company has outstanding warrants issued in connection with the PIPE financing and prior bridge arrangements. These warrants are exercisable at prices ranging from $11.50 to $16.00 per share and have terms of up to five years. As of September 30, 2026, liability-classified warrants to purchase 4,465,591 ordinary shares were outstanding: PIPE Warrants to purchase 1,841,750 shares at $12.00 and 920,875 shares at $16.00, with a remaining contractual term of approximately 4.0 years, and Bridge Loan Warrants to purchase 851,483 shares at $11.50 and 851,483 shares at $15.00, with a remaining contractual term of approximately 2.0 years. Together with the 1,000,000 equity-classified warrants, warrants to purchase 5,465,591 ordinary shares were outstanding as of September 30, 2026.

 

The warrants are classified as liabilities as they are not considered indexed to the Company’s functional currency in accordance with ASC 815-40. As a result, the warrants are recorded at fair value upon issuance and remeasured at fair value at each reporting date, with changes in fair value recognized in the interim consolidated statements of operations.

 

14

 

 

Certain of these warrants were issued in connection with bridge loans that were outstanding prior to the Business Combination and were converted into equity at Closing. Before Closing, the warrants issuable to the Bridge Loan lenders were classified in equity by Legacy Terra, including $193 reclassified from liabilities in June 2025 upon resolution of a contingency affecting the number of shares issuable, and are presented within additional paid-in capital in the 2025 consolidated statement of changes in shareholders’ deficit. Upon their issuance by the Company at Closing, the Bridge Loan Warrants, which have exercise prices denominated in U.S. dollars, were classified as liabilities because they are not indexed to the Company’s own stock given its euro functional currency.

 

The following table summarizes the activity in the Company’s warrant liabilities for the period ended September 30, 2026:

 

    PIPE
Warrants
    Bridge Loan
Warrants
    Total  
Balance as of January 1, 2026   $ 5,931     $ 4,305     $ 10,236  
Loss (gain) recognized in earnings due to change in fair value, including foreign currency remeasurement impact     71       (154 )     (83 )
Foreign currency translation     (121 )     (83 )     (204 )
Balance as of March 31, 2026     5,881       4,068       9,949  
Loss recognized in earnings due to change in fair value, including foreign currency remeasurement impact     590       73       663  
Foreign currency translation     (62 )     (37 )     (99 )
Balance as of June 30, 2026     6,409       4,104       10,513  
Gain recognized in earnings due to change in fair value, including foreign currency remeasurement impact     (3,057 )     (2,205 )     (5,262 )
Foreign currency translation     40       29       69  
Balance as of September 30, 2026   $ 3,392     $ 1,928     $ 5,320  

  

Refer to Note 8 – Fair Value Measurements for additional information regarding the valuation of the warrant liabilities.

 

Note 10. Shareholders’ Deficit

 

Authorized Share Capital

 

The Company is authorized to issue 500,000,000 ordinary shares with a par value of €0.01 per share and 8,040 convertible preferred shares with a par value of €100 per share. Upon conversion of one or more of the convertible preferred shares into ordinary shares, the authorized share capital shall decrease with the number of convertible preferred shares so converted and shall increase with the number of ordinary shares into which such convertible preferred shares were converted.

 

Vesting Sponsor Shares

 

In connection with the Business Combination, 549,500 ordinary shares were issued as vesting Sponsor shares. As of September 30, 2026, the first two of four equal tranches (274,750 shares) have vested upon achievement of the related regulatory milestones, and the remaining 274,750 shares remain subject to the vesting conditions described in Note 8. The unvested shares are classified as a share-settled contingent liability in the consolidated balance sheets. The unvested Sponsor shares are legally issued and outstanding; however, because they are classified as a share-settled contingent liability, they are excluded from the ordinary shares issued and outstanding presented in the consolidated balance sheets and the consolidated statements of changes in shareholders’ deficit.

 

Convertible Preferred Shares

 

The Company issued 8,000 convertible preferred shares that are mandatorily convertible into ordinary shares upon achievement of specified milestones. As of September 30, 2026, 4,000 shares have converted into ordinary shares, and the remaining 4,000 shares are legally outstanding and are classified as share-settled contingent liabilities. Because these 4,000 shares are liability-classified, they are not included in the 20 convertible preferred shares presented within shareholders’ deficit in the consolidated balance sheets and the consolidated statements of changes in shareholders’ deficit, which represent the equity-classified SPAC financial advisor preferred shares described below. Each convertible preferred share converts into 10,000 ordinary shares. The remaining 4,000 liability-classified convertible preferred shares are convertible into 40,000,000 ordinary shares (20,000,000 for each of the third and fourth tranches), and the 20 equity-classified SPAC financial advisor preferred shares are convertible into 200,000 ordinary shares.

 

SPAC Financial Advisor Preferred Shares

 

The Company issued 40 convertible preferred shares to a financial advisor as share-based compensation. As of September 30, 2026, 20 shares have converted into ordinary shares and 20 remain outstanding. These awards are classified in equity and accounted for under ASC 718.

 

15

 

 

Share-Based Compensation

 

On September 22, 2026, the Company granted 200,000 restricted ordinary shares under its 2025 Equity Incentive Plan to three service providers, with a service inception date of January 27, 2026: 180,000 shares vesting in 36 equal monthly installments through December 31, 2028, 10,000 shares vesting in monthly installments through June 30, 2027, and 10,000 shares that vested in monthly installments through August 31, 2026. The grant-date fair value was $808 ($4.04 per share), and compensation cost is recognized on a straight-line basis over the service period. Stock-based compensation expense of $243 was recognized in general and administrative expenses for the three and nine months ended September 30, 2026. As of September 30, 2026, 59,706 shares had vested, of which 54,117 were issued on September 25, 2026; the remaining 5,589 shares vested on September 30, 2026 and had not yet been issued. The 140,294 unvested shares will be issued as they vest. Unrecognized compensation cost was $565, expected to be recognized over a weighted-average period of approximately 2.2 years.

 

Ordinary Shares Issued and Outstanding

 

The 110,280,315 ordinary shares presented as issued and outstanding as of September 30, 2026 exclude the 274,750 unvested Sponsor shares, which are legally issued and outstanding but are classified as a share-settled contingent liability (Note 8). In addition, the transfer agent has registered 145,883 ordinary shares under the 2025 Equity Incentive Plan in respect of the 140,294 unvested restricted shares and the 5,589 restricted shares that vested on September 30, 2026. These shares had not been issued to the award holders, are not considered issued and outstanding, and are expected to be cancelled, with shares issued to the holders as the awards vest. The 4,000 liability-classified convertible preferred shares are legally outstanding but are excluded from the convertible preferred shares presented in shareholders’ deficit, as described above.

 

Warrants

 

See Note 9 – Warrants for additional information.

 

Note 11. Commitments and Contingencies

 

Investor Relations and Advisory Services Agreements

 

The Company has an investor relations and advisory agreement under which it pays a fixed monthly fee of $25, covering up to 84 hours of investor relations, communications and business-development services, along with certain variable charges, including a 3% monthly service fee for access to market-intelligence platforms and additional services billed at the vendor’s standard hourly rates. The agreement automatically renewed in April 2026 for an additional one-year term through April 30, 2027, and renews annually thereafter unless terminated by either party with 60 days’ notice.

 

Capital Markets Advisory Agreements

 

The Company has entered into various capital markets advisory agreements with third-party service providers. These agreements include fixed fee commitments payable over contractual terms ranging from approximately one to two years. Certain agreements include customary termination and change-in-control provisions. As of September 30, 2026, remaining fixed fees payable under these agreements totaled $833, of which $533 is payable during the remainder of 2026 and $300 in 2027. Of these amounts, $600 is payable under a 24-month agreement entered into on October 14, 2025 ($300 on each of the first and second anniversaries of the agreement), which is subject to reduction by fees paid to the vendor for other transactions and becomes immediately payable upon a change of control.

 

Engineering and Development Agreements

 

The Company has entered into agreements with third-party vendors to support engineering, licensing, and development activities related to the SOLO project. Payments under these agreements are based on contractual milestones, time-based services, or invoiced amounts. As of September 30, 2026, remaining noncancelable commitments under these agreements totaled approximately $4,302, including $251 (€221) under the engineering services agreement with Nine described in Note 3, and are expected to be paid through December 31, 2027. Milestone-based payments are contingent on the achievement of the related milestones; the amounts payable if all remaining milestones are achieved total approximately $1,119.

 

Senior Advisor Agreement

 

The Company has an agreement with an independent contractor providing strategic advisory services. Compensation under the agreement includes potential equity-based awards and a commission on qualifying business opportunities. As of September 30, 2026, no equity awards have been granted under this arrangement.

 

16

 

 

Note 12. Net Income (Loss) Per Share

 

The Company completed a business combination on October 9, 2025, which was accounted for as a recapitalization. Accordingly, historical share information has been retroactively restated to reflect 47,500,000 ordinary shares for periods prior to Closing.

 

Basic and diluted net income (loss) per ordinary share attributable to ordinary shareholders were calculated as follows (in thousands except share and per share amounts):

 

    For the Three Months Ended
September 30,
    For the Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Net income (loss)   $ 61,027     $ (2,987 )   $ 35,877     $ (5,580 )
Weighted- average ordinary shares outstanding - basic     110,231,553       47,500,000       110,228,003       47,500,000  
Weighted-average ordinary shares outstanding - diluted
    110,234,376       47,500,000       110,229,053       47,500,000  
Basic and diluted net income (loss) per ordinary share   $ 0.55     $ (0.06 )   $ 0.33     $ (0.12 )

 

For the three and nine months ended September 30, 2026, potential ordinary shares related to the share-settled contingent liability (convertible preferred shares and unvested Sponsor shares) were excluded from diluted EPS as the applicable issuance or vesting conditions were not satisfied as of the reporting date.

 

In addition, liability-classified PIPE and Bridge Warrants and equity-classified warrants were evaluated under the treasury stock method. For the three and nine months ended September 30, 2026, the average market price of the Company’s ordinary shares ($5.07 and $5.21, respectively) was below the exercise prices of all outstanding warrants; accordingly, all such instruments were anti-dilutive and therefore excluded from diluted EPS.

 

The following potential ordinary shares were excluded from the computation of diluted net income (loss) per share because their effect was anti-dilutive or the conditions for their issuance or vesting had not been satisfied as of the end of the period: approximately 45,940,341 potential ordinary shares as of September 30, 2026, consisting of 40,200,000 ordinary shares issuable on conversion of the convertible preferred shares, 5,465,591 ordinary shares issuable on exercise of warrants (4,465,591 liability-classified PIPE and Bridge Loan Warrants and 1,000,000 equity-classified warrants), and 274,750 unvested Sponsor shares. The third and fourth tranche share price targets and regulatory milestones had not been achieved as of September 30, 2026. Diluted weighted-average ordinary shares also include the incremental shares from the 140,294 unvested restricted shares, calculated under the treasury stock method, which did not change diluted net income per share. As a result, diluted net income (loss) per share equals basic net income (loss) per share for the periods presented. For the three and nine months ended September 30, 2025, the Company reported a net loss, and the ordinary shares and warrants issuable upon conversion of the Bridge Loans, which were contingent on the consummation of the Business Combination, were excluded from diluted net loss per share.

 

Note 13. Segment Information

 

The Company is a development-stage nuclear energy technology company focused on the research, development, and future commercialization of its SOLO micro-modular nuclear reactor. The chief operating decision maker (“CODM”), consisting of the Company’s chief executive officer and founding officers acting collectively, reviews financial information on a consolidated basis for purposes of evaluating performance and allocating resources. The CODM does not review discrete financial information by product, function, or geographic location. As a result, the Company has determined that it operates as a single operating segment, which is also its sole reportable segment. The measure of segment profit or loss is consolidated net income (loss), and segment assets are total consolidated assets, as reported in the interim consolidated financial statements. The CODM uses consolidated net income (loss), together with the significant segment expenses presented below, to monitor results against budget, assess performance and decide how to allocate resources, primarily between development activities and general and administrative functions. The CODM is regularly provided with general and administrative expenses and development costs in total. The Company has not generated revenue from external customers, as its SOLO product remains under development.

 

17

 

 

Significant segment expenses, other segment items and segment net income (loss) were as follows:

 

    For the Three Months Ended September 30,     For the Nine Months Ended September 30,  
    2026     2025     2026     2025  
Operating expenses:                                
General and administrative   $ 5,437     $ 2,135     $ 15,431     $ 5,655  
Development costs     1,657       155       4,376       244  
Total operating expenses   $ 7,094     $ 2,290     $ 19,807     $ 5,899  
Loss from operations     (7,094 )     (2,290 )     (19,807 )     (5,899 )
Other segment items:                                
Change in fair value - share-settled contingent liability     62,209       -       46,382       -  
Change in fair value - warrant liabilities     5,262       -       4,682       1,260  
Other income (expense), net     650       (697 )     4,620       (941 )
Provision for income taxes     -       -       -       -  
Segment and consolidated net income (loss)   $ 61,027     $ (2,987 )   $ 35,877     $ (5,580 )

 

Note 14. Income Taxes

 

For the three and nine months ended September 30, 2026, the Company recognized no income tax benefit or expense on pretax income of $61,027 and $35,877, respectively, resulting in an effective tax rate of 0% for each period. For the three and nine months ended September 30, 2025, the Company recognized no income tax benefit or expense on pretax losses of $2,987 and $5,580, respectively, resulting in an effective tax rate of 0% for each period. Pretax income primarily reflects non-cash gains from changes in the fair value of the share-settled contingent liability and warrant liabilities, which are not subject to income tax. These gains arise only under U.S. GAAP and are not recognized in the statutory financial statements of the Company (prepared under Dutch GAAP, as required by Dutch corporate law) or Legacy Terra (prepared under Italian GAAP), on which taxable income is based. No current income tax was due for the nine months ended September 30, 2026. The Company maintained a full valuation allowance against its net deferred tax assets as of September 30, 2026, based on its determination that it is more likely than not that the Company’s net deferred tax assets will not be realized. Although the Company is incorporated in the Netherlands, it is subject to Italian corporate income tax, as described in Note 2; the reference to Dutch GAAP describes the basis of its statutory financial statements, not its tax jurisdiction. Income tax receivables of $558 as of September 30, 2026 (Note 4) consist principally of Italian withholding taxes on bank interest income, which are creditable against Italian corporate income tax.

 

Note 15. Subsequent Events

 

On October 5, 2026, TerraUS signed an amendment to its consulting agreement with FPoli, a related party, effective August 1, 2026 (see Note 3). The 145,883 ordinary shares registered by the transfer agent under the 2025 Equity Incentive Plan that are not considered issued and outstanding (see Note 10) are expected to be cancelled. In October 2026, the Company announced an industrial manufacturing program with ATB and Boldrocchi and the procurement of components for its first reactor; the Company had not entered into binding purchase commitments under these arrangements other than those included in Note 11.

 

18

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following discussion and analysis provides information that Terra Innovatum Global N.V. (the “Company” or “Terra”) management believes is relevant to an assessment and understanding of the Company’s results of operations and financial condition. This discussion should be read together with the Company’s unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2026 and 2025, and the related notes included elsewhere in this Form 10-Q. All amounts in thousands except share and per share amounts.

 

This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. The Company’s actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 and in other parts of this Form 10-Q.

 

Presentation of Financial Information

 

Beginning with the quarterly report on Form 10-Q for the three and nine months ended September 30, 2025, we have elected to present all dollar amounts rounded to the nearest thousand dollars, unless otherwise indicated. In prior periods, including those presented in the Form S-4 Amendment No. 5 filed on September 11, 2025, financial information was presented in whole dollars. This change has been made to enhance the readability and consistency of financial disclosures. As a result, certain prior period amounts may not be directly comparable due to rounding differences.

 

Company Overview

 

We are a pioneering nuclear energy technology company developing the SOLO™ Micro-Modular Nuclear Reactor (“SOLO”), a breakthrough solution designed to address critical challenges in affordable, clean, decentralized energy production. Our reactor represents a significant technological and engineering advancement, offering a compact, safe, and economically compelling alternative to traditional energy generation and supply solutions. The SOLO reactor’s core innovation lies in its ability to generate 1 MWe of electricity baseload with a continuous operational cycle of up to 15 years, extendable to 45 years through refueling, with a fixed and competitive projected levelized cost of energy. Our strategic roadmap targets commercial deployment by 2028, with a clear focus on delivering a scalable, modular nuclear solution that can be deployed across diverse markets — from industrial and infrastructure to remote and off-grid applications. Key differentiators include a gas-cooled design, multiple safety shutdown mechanisms, safeguard-by-design, small footprint, and the ability to use commercially available Low Enriched Uranium (“LEU”), which significantly reduces regulatory and technological barriers typical in nuclear energy development. We have made substantial progress in de-risking our First-of-a-Kind (“FOAK”) reactor, including initiating regulatory engagement with the U.S. Nuclear Regulatory Commission (“NRC”), and establishing a robust supply chain strategy. We have completed the reactor design sufficiently to support component fabrication and NRC licensing, validated key technological components, and are targeting licensing and deployment of the FOAK reactor by 2028.

 

Recent Developments

 

Lease Agreement

 

On January 2, 2026, we entered into a lease for office space in Lucca, Italy, with a noncancelable term commencing April 1, 2026 and expiring March 31, 2032. The lease provides for annual base rent of approximately $85 (€75), which is adjusted annually in accordance with the variation in the consumer price index published by the Italian National Institute of Statistics (“ISTAT”), as required under Italian commercial lease law. These index-based rent adjustments are variable lease payments and are recognized as expense in the period incurred; they are not included in the measurement of our lease liability or right-of-use asset.

 

U.S. Subsidiary

 

Terra Innovatum Corp. (“TerraUS”), a wholly owned U.S. subsidiary formed in December 2025, began operations in April 2026 to support U.S. regulatory engagement with the NRC and related development activities. As of September 30, 2026, the Company had funded TerraUS with $4,500.

 

Financial Performance

 

For the three months ended September 30, 2026 and 2025, we reported net income of $61,027 and a net loss of $2,987, respectively.

 

For the nine months ended September 30, 2026 and 2025, we reported net income of $35,877 and a net loss of $5,580, respectively. Net cash used in operating activities was $19,626 for the nine months ended September 30, 2026 compared to net cash used of $3,688 for the nine months ended September 30, 2025.

 

19

 

 

Key Factors and Trends Affecting Our Business and Results of Operations

 

We believe the following factors and trends may cause previously reported financial information not to be necessarily indicative of future operating results or future financial conditions:

 

Product Development Plan. The commercial rollout of advanced nuclear reactors depends on securing regulatory approvals for its design, construction, and operation. Our regulatory engagement plan was submitted to the NRC, and the NRC is currently reviewing a number of safety related topics related to SOLO. Although our team has significant prior experience working with the NRC, we cannot control NRC’s review process and review periods may take longer than anticipated.

 

Funding and Investment. There can be no assurance that sufficient funding will be available to us to fund our operating expenses and to further develop our business. We anticipate that we will likely need to raise additional capital to fund our operations while we implement and execute our business plan. While we believe that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months (see “Liquidity and Capital Resources” below), we will need additional capital to complete our reactor development, to successfully market our reactors and to achieve commerciality for our reactors. We have encountered and expect to continue to encounter risks and uncertainties frequently experienced by companies in rapidly evolving industries. Accordingly, we may be unable to prepare accurate internal financial forecasts or replace anticipated revenue that we do not receive as a result of delays, changed circumstances, or changed market conditions arising from these factors, and our results of operations in future reporting periods may be below the expectations of investors or analysts.

  

Macroeconomic Conditions and Global Market Dynamics. Our business operates in a complex global environment with multiple interconnected economic factors that can significantly impact our technological development, regulatory trajectory, and potential market penetration. As a nuclear technology company with an international human capital strategy and multinational supply chain, we are sensitive to macroeconomic trends and risks.

 

Global Supply Chain Dynamics. We utilize a strategic outsourced manufacturing approach for the SOLO project, leveraging international human resources and implementing an international manufacturing model for our FOAK reactor. This strategy exposes us to global supply chain vulnerabilities, including potential impacts from geopolitical tensions, trade agreements, tariffs, and manufacturing disruptions.

 

By partnering with specialized suppliers certified in nuclear engineering and precision manufacturing, we aim to avoid significant capital investments in manufacturing facilities and concentrate our resources on core competencies such as reactor design, technological innovation, and regulatory compliance. Our procurement strategy involves direct engagement with multiple suppliers for critical components, ensuring supply chain reliability and maintaining the flexibility to adapt our technology to evolving market and regulatory requirements.

 

Inflation and Cost Pressures. Inflationary trends represent a risk to our development trajectory. Escalating costs in specialized manufacturing, regulatory compliance, technical talent acquisition, and raw material procurement could potentially erode our projected economic advantages.

 

Energy Market Evolution. The global energy transition, driven by decarbonization efforts and increasing demand for reliable low-carbon baseload power, creates both opportunities and challenges. The explosive growth in data center energy requirements, particularly with artificial intelligence (“AI”) and computational infrastructure expansion, presents a promising market segment. However, economic growth cycles, shifts in energy policy, and potential slowdowns in technological adoption could materially affect our market positioning and revenue projections.

 

To mitigate the AI-driven market concentration risks, we have strategically designed SOLO with multi-sector versatility, targeting a diverse range of energy-intensive industries including industrial manufacturing (cement, steel, mining, paper production), critical infrastructure services (airports, ports, logistics hubs), agricultural and food processing applications (greenhouses, vertical farming, food processing plants), energy storage (ammonia production, pink hydrogen) and essential utility services like desalination and water treatment. This intentional market diversification allows us to create resilience against sector-specific economic fluctuations, leveraging SOLO’s ability to provide both electricity and thermal energy across multiple high-demand sectors, including emerging opportunities in medical radioisotope production.

 

Regulatory and Geopolitical Landscape. Our multinational operational model requires navigating complex regulatory environments across different jurisdictions. Changes in nuclear energy policies and geopolitical tensions could significantly impact our potential market access. The evolving global stance on nuclear energy, particularly small modular reactors, introduces both strategic opportunities and potential regulatory constraints.

 

Technological and Labor Market Dynamics. The specialized nature of our technology demands access to a global pool of highly skilled technical talent. Potential labor market shifts, competition for specialized nuclear engineering expertise, and varying international education and training standards could influence our human resource strategy and technology development velocity.

 

Economic Uncertainty Factors. Macroeconomic uncertainties, including potential recessionary periods, fluctuations in investment trends in energy related technology, and broader economic growth patterns, could affect our funding capabilities, customer acquisition strategies, and overall business development trajectory.

 

20

 

 

Emerging Growth Company and Smaller Reporting Company Status

 

Section 102(b)(1) of the Jumpstart Our Business Startups Act (“JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. Until we are no longer considered to be an emerging growth company, we have elected not to opt out of such extended transition period which means that when an accounting standard is issued or revised and it has different application dates for public or private companies, as an emerging growth company, we can adopt the new or revised standard at the time private companies adopt the new or revised standard.

 

We are also a “smaller reporting company” as defined in the Securities Exchange Act of 1934. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting ordinary shares held by non-affiliates is $250,000 or more measured on the last business day of our second fiscal quarter, or our annual revenues equal or exceed $100,000 during the most recently completed fiscal year and our voting and non-voting ordinary shares held by non-affiliates is $700,000 or more measured on the last business day of our second fiscal quarter.

 

Segment Reporting

 

We are a development-stage nuclear energy technology company focused on the research, development, and future commercialization of our SOLO micro-modular nuclear reactor. Our chief operating decision maker (“CODM”), consisting of our chief executive officer and founding officers acting collectively, reviews financial information on a consolidated basis for purposes of evaluating performance and allocating resources. The CODM does not review discrete financial information by product, function, or geographic location. As a result, we have determined that we operate as a single operating segment, which is also our sole reportable segment. The measure of segment profit or loss is consolidated net income (loss), and segment assets are total consolidated assets, as reported in the interim consolidated financial statements. The CODM uses consolidated net income (loss), together with the significant segment expenses presented below, to monitor results against budget, assess performance and decide how to allocate resources, primarily between development activities and general and administrative functions. We have not generated revenue from external customers, as our SOLO product remains under development.

 

Results of Operations

 

The period-to-period comparisons of our results of operations have been prepared using the historical periods included in our financial statements. The following discussion should be read in conjunction with the financial statements and related notes included elsewhere in this Form 10-Q.

 

Key Components of Results of Operations

 

Revenue

 

To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future.

 

Operating Expenses

 

General and administrative

 

Our general and administrative expenses consist primarily of advisory fees, legal fees, audit, accounting, professional services fees, insurance, Board of Director compensation, software costs, transportation, food and lodging, conference and seminar registration fees, advertising, rental, filing fees, employee benefits, consultancy fees, representation expenses, commissions, and other miscellaneous expenses.

 

Development costs

 

Development costs represent costs incurred to design and engineer SOLO. These costs include technical consulting and personnel-related expenses (such as salaries, employee benefits, and bonuses), software and computing costs, hardware and experimental supplies, and fees for outside engineering, analytical, and consulting services.

 

21

 

 

Other Income (Expenses)

 

Other income (expenses)

 

Our other income (expenses) primarily consists of foreign currency transaction gains and losses, as well as interest income.

 

Change in fair value – share settled contingent liability

 

In connection with the Business Combination, we issued 8,000 convertible preferred shares (of which 4,000 converted in 2025, with 4,000 remaining unvested) to former Terra Innovatum Global Srl. quotaholders that are mandatorily convertible into our ordinary shares upon the achievement of specified market-based and regulatory milestones (the “Convertible Preferred Shares”). Together with Sponsor ordinary shares subject to similar vesting conditions, the Convertible Preferred Shares will be settled through the issuance of a variable number of our ordinary shares (together, the “Share-Settled Contingent Liability”). Because these instruments settle in a variable number of shares and are not indexed solely to our stock price, they do not qualify for equity classification under ASC 815-40 and ASC 480-10 and are instead recorded as a liability. We remeasure the Share-Settled Contingent Liability to fair value at each reporting date using a Monte Carlo simulation model until the underlying milestones are achieved or expire, with changes recognized in our interim consolidated statements of operations. Because this valuation is highly sensitive to our share price, expected volatility, and the probability-weighted timing of milestone achievement, period-to-period changes can be large relative to our other results of operations and are non-cash in nature.

 

Change in fair value — warrant liabilities

 

The change in fair value — warrant liabilities consists of the change in fair value of certain PIPE and Bridge Loan warrants.

 

Provision for income taxes

 

Provision (or benefit) for income taxes consists of the expense or income related to income taxes.

 

Results of Operations

 

The Three Months Ended September 30, 2026 Compared to the Three Months Ended September 30, 2025

 

The following table sets forth our results for the periods indicated and the changes between periods:

 

    For The Three Months
Ended September 30,
       
    2026     2025     $ Variance     % Variance  
Operating expenses:                        
General and administrative   $ 5,437     $ 2,135     $ 3,302       155 %
Development costs     1,657       155       1,502       NM  
Total operating expenses     7,094       2,290       4,804       210 %
Loss from operations     (7,094 )     (2,290 )     (4,804 )     210 %
Other income (expenses):                                
Other income (expenses)     650       (697 )     1,347       NM  
Change in fair value - share settled contingent liability     62,209       -       62,209       NM  
Change in fair value - warrant liabilities     5,262       -       5,262       NM  
Total other (expense) income, net     68,121       (697 )     68,818       NM  
Income (loss) before income taxes     61,027       (2,987 )     64,014       NM  
(Provision) benefit for income taxes     -       -       -       -  
Net income (loss)   $ 61,027     $ (2,987 )   $ 64,014       NM  

 

NM – not meaningful

 

Operating Expenses

 

General and administrative

 

General and administrative expenses increased by $3,302 for the three months ended September 30, 2026 compared to the same period in 2025, primarily due to the costs of operating as a public company following the Business Combination and the build-out of our U.S. operations. General and administrative expenses for the three months ended September 30, 2026 included (i) $2,485 of professional, legal and advisory fees, (ii) $838 of personnel costs, principally of TerraUS, (iii) $737 of Board of Director compensation, including $320 paid in cash to four directors in lieu of equity awards, (iv) $715 of insurance, principally directors’ and officers’ liability insurance, (v) $174 of investor relations, listing and marketing costs, and (vi) $243 of stock-based compensation. General and administrative expenses and development costs for the three months ended September 30, 2026 include approximately $800 of TerraUS expenses for April through June 2026 that were recorded in the third quarter (see Note 2 to the interim consolidated financial statements). The 2025 period reflects the results of Legacy Terra only, prior to the Business Combination.

 

22

 

 

We expect to continue to incur additional general and administrative expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq Stock Market, additional insurance costs, investor relations activities and other administrative and professional services. As a result, we expect general and administrative expenses to increase in absolute dollars in future periods.

 

Development costs

 

Development costs increased by $1,502 for the three months ended September 30, 2026 compared to the same period in 2025, reflecting the expansion of our SOLO development program. Development costs for the three months ended September 30, 2026 consisted primarily of (i) $1,237 of technical consultancy and engineering studies, including $512 of engineering, quality assurance and licensing consultants and $281 of U.S. NRC pre-application review fees incurred by TerraUS, and (ii) $417 of personnel costs for our engineering staff.

 

Other Income (Expenses)

 

Other income (expenses)

 

Other income was $650 for the three months ended September 30, 2026, which primarily consists of $530 of interest income on our U.S. dollar deposits and $119 of net foreign currency gains.

 

Other expenses was $697 for the three months ended September 30, 2025, which primarily consists of $537 of interest expense and $160 of other expenses, net.

 

Change in fair value – share settled contingent liability

 

There was a $62,209 unrealized gain attributable to the change in fair value of the share settled contingent liability for the three months ended September 30, 2026, based on the September 30, 2026 valuation and net of the related foreign currency remeasurement. There was no share settled contingent liability during the same period in 2025. The gain primarily reflects the decrease in our share price to $3.39 as of September 30, 2026 from $4.92 as of June 30, 2026. Because management estimates a high probability of achieving the remaining regulatory milestones (approximately 89% and 80%, expected between June and October 2027 and between December 2027 and March 2028, respectively), the fair value of the remaining tranches moves closely with our share price.

 

Change in fair value — warrant liabilities

 

The $5,262 unrealized gain in fair value attributable to warrant liabilities for the three months ended September 30, 2026 consists of the change in fair value of certain PIPE ($3,057) and Bridge Loan ($2,205) warrants, including foreign currency remeasurement. The decrease in fair value primarily reflects the decrease in our share price during the quarter. There was no change in fair value attributable to warrant liabilities during the same period in 2025.

 

Provision for income taxes

 

The provision for income taxes was $0 for the three months ended September 30, 2026 and 2025.

 

Net income (loss)

 

Net income for the three months ended September 30, 2026 was $61,027 compared to a net loss of $2,987 for the three months ended September 30, 2025. The $64,014 change was primarily due to gains of $62,209 and $5,262 from changes in the fair value of the share settled contingent liability and warrant liabilities, respectively, and a $1,347 increase in other income (expenses), net, partially offset by a $4,804 increase in operating expenses.

 

23

 

 

The Nine Months Ended September 30, 2026 Compared to the Nine Months Ended September 30, 2025

 

The following table sets forth our results for the periods indicated and the changes between periods:

 

    For The Nine Months
Ended September 30,
       
    2026     2025     $ Variance     % Variance  
Operating expenses:                        
General and administrative   $ 15,431     $ 5,655     $ 9,776       173 %
Development costs     4,376       244       4,132       NM  
Total operating expenses     19,807       5,899       13,908       236 %
Loss from operations     (19,807 )     (5,899 )     (13,908 )     236 %
Other income (expenses):                                
Other income (expenses)     4,620       (941 )     5,561       NM  
Change in fair value - share settled contingent liability     46,382       -       46,382       NM  
Change in fair value - warrant liabilities     4,682       1,260       3,422       272 %
Total other (expense) income, net     55,684       319       55,365       NM  
Income (loss) before income taxes     35,877       (5,580 )     41,457       NM  
(Provision) benefit for income taxes     -       -       -       -  
Net income (loss)   $ 35,877     $ (5,580 )   $ 41,457       NM  

 

NM – not meaningful

 

Operating Expenses

 

General and administrative

 

General and administrative expenses increased by $9,776 for the nine months ended September 30, 2026 compared to the same period in 2025, primarily due to the costs of operating as a public company following the Business Combination and the build-out of our U.S. operations. General and administrative expenses for the nine months ended September 30, 2026 included (i) $9,271 of professional, legal and advisory fees, (ii) $2,011 of insurance, principally directors’ and officers’ liability insurance, (iii) $1,858 of Board of Director compensation, including $320 paid in cash to four directors in lieu of equity awards, (iv) $840 of personnel costs, principally of TerraUS, (v) $406 for travel, food and lodging, (vi) $320 of investor relations, listing and marketing costs, (vii) $210 for rent, office and IT costs, and (viii) $243 of stock-based compensation. TerraUS began operations in April 2026, and its expenses for April through June 2026 were recorded in the three months ended September 30, 2026; as a result, substantially all TerraUS personnel costs for the nine months are also included in the third quarter. The 2025 period reflects the results of Legacy Terra only, prior to the Business Combination.

 

We expect to continue to incur additional general and administrative expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq Stock Market, additional insurance costs, investor relations activities and other administrative and professional services. As a result, we expect general and administrative expenses to increase in absolute dollars in future periods.

 

Development costs

 

Development costs increased by $4,132 for the nine months ended September 30, 2026 compared to the same period in 2025, reflecting the expansion of our SOLO development program. Development costs for the nine months ended September 30, 2026 consisted primarily of (i) $3,329 of technical consultancy and engineering studies, including $512 of engineering, quality assurance and licensing consultants and $281 of U.S. NRC pre-application review fees incurred by TerraUS, and (ii) $1,013 of personnel costs for our engineering staff. As with general and administrative expenses, the TerraUS consultant and NRC fees for the nine months were recorded in the third quarter.

 

Other Income (Expenses)

 

Other income (expenses)

 

Other income was $4,620 for the nine months ended September 30, 2026, which primarily consists of $2,934 of net foreign currency gains, principally from remeasuring U.S. dollar cash held by our euro-functional entities, and $1,686 of interest income.

 

Other expenses was $941 for the nine months ended September 30, 2025, which primarily consists of $726 of interest expense and $215 of other expenses, net.

 

Change in fair value – share settled contingent liability

 

There was a $46,382 unrealized gain attributable to the change in fair value of the share settled contingent liability for the nine months ended September 30, 2026, reflecting losses of $15,827 in the first six months of 2026 and a gain of $62,209 in the third quarter. There was no share settled contingent liability during the same period in 2025.

 

24

 

 

Change in fair value — warrant liabilities

 

The $4,682 unrealized gain in fair value attributable to warrant liabilities for the nine months ended September 30, 2026 consists of the change in fair value of certain PIPE ($2,396) and Bridge Loan ($2,286) warrants. There was $1,260 unrealized gain in fair value attributable to certain Bridge Loan warrant liabilities during the same period in 2025.

 

Provision for income taxes

 

The provision for income taxes was $0 for the nine months ended September 30, 2026 and 2025.

 

Net income (loss)

 

Net income for the nine months ended September 30, 2026 was $35,877 compared to a net loss of $5,580 for the nine months ended September 30, 2025. The $41,457 change was primarily due to the $46,382 gain from the change in fair value of the share settled contingent liability, a $3,422 favorable change in the fair value of warrant liabilities and a $5,561 increase in other income, net, partially offset by a $13,908 increase in operating expenses.

 

Liquidity and Capital Resources

 

Liquidity represents our ability to generate sufficient cash to support ongoing operations, meet obligations, and fund future growth. Since inception, we have financed our activities primarily through the net proceeds of the Business Combination and the PIPE financing and the Bridge Loans and, to a lesser extent, loans from our former quotaholders and capital contributions, as we have not yet generated revenue from our core operations. We do not expect to generate meaningful revenue unless and until we complete development, obtain regulatory licenses, and enter the commercialization phase of the SOLO, which we do not anticipate before 2028. Accordingly, we are dependent on our existing cash resources to fund operations while we advance toward commercialization. In the short term, our liquidity is supported by the proceeds received upon closing the Business Combination on October 9, 2025 (“Closing”), which, together with the related PIPE financing, generated net proceeds of approximately $106,713. At Closing, all outstanding Bridge Loans converted into 851,483 ordinary shares at a price of $7.00 per share, eliminating near-term debt service commitments. We expect to outsource manufacturing activities, which reduces near-term capital expenditure requirements.

 

As of September 30, 2026, we had cash and cash equivalents of $82,372 and an accumulated deficit of $571,399. Net cash used in operating activities was $19,626 for the nine months ended September 30, 2026. We have historically incurred recurring operating losses and generated negative cash flows from operations as we are a pre-revenue company developing technology and looking towards commercialization in 2028.

 

We continue to evaluate and pursue potential liquidity-enhancing actions, which may include equity or debt financing, strategic transactions, or other funding arrangements; however, no definitive agreements are currently in place. Based on our current operating plan, we believe that our existing cash and cash equivalents of $82,372 as of September 30, 2026 will be sufficient to fund our operating expenses, capital expenditures and contractual commitments for at least the next 12 months from the date of issuance of the unaudited consolidated financial statements included in this Form 10-Q, consistent with management’s going concern evaluation described in Note 2 to those financial statements. We expect, however, to require additional capital to complete the development, licensing and commercialization of SOLO.

 

Our primary sources of liquidity are cash on hand, and our primary uses of liquidity are operating expenses and licensing activities. We continue to actively monitor our liquidity position and may seek additional financing, including future equity offerings, strategic arrangements, or other capital-raising transactions, to support our long-term development and commercialization strategy.

 

Contractual Obligations and Commitments

 

Our contractual obligations consist primarily of our office lease (see Note 6) and fixed-fee and milestone-based commitments under investor relations, capital markets advisory, and engineering and development agreements (see Note 11). As of September 30, 2026, remaining commitments under these agreements totaled approximately $5,421, of which the full amount is expected to be paid within the next 12 months. We expect to fund these commitments from existing cash and cash equivalents.

 

Cash Flows

 

The following table provides detailed information about our net cash flows for the nine months ended September 30, 2026 and 2025:

 

    For The Nine Months
Ended September 30,
 
    2026     2025  
Net cash (used in) provided by:            
Operating activities   $ (19,626 )   $ (3,688 )
Investing activities     (924 )     (94 )
Financing activities     -       5,759  
Effect of exchange rate changes on cash     40       105  
Net (decrease) increase in cash   $ (20,510 )   $ 2,082  

 

25

 

 

Operating Activities

 

Net cash used by operating activities for the nine months ended September 30, 2026 was $19,626. This amount was primarily driven by (i) net income of $35,877, (ii) non-cash adjustments of $(53,692), principally gains of $46,382 and $4,682 from changes in the fair value of the share-settled contingent liability and warrant liabilities, respectively, and unrealized foreign exchange gains of $2,934, (iii) net working capital decreases of $1,827, principally advances to engineering suppliers and value added tax receivable, partially offset by higher accrued expenses, (iv) a decrease in operating lease liabilities of $25, and (v) an increase in other non-current liabilities of $41.

 

Net cash used by operating activities for the nine months ended September 30, 2025 was $3,688. This amount was primarily attributable to (i) net loss of $5,580, (ii) non-cash adjustments of $(599), (iii) net working capital increases of $2,394, and (iv) an increase in other non-current liabilities of $97.

 

Investing Activities

 

Net cash used by investing activities for the nine months ended September 30, 2026 was $924, which was related to purchases of equipment and software. Net cash used by investing activities for the nine months ended September 30, 2025 was $94, which was related to the purchases of equipment.

 

Financing Activities

 

There was no net cash from financing activities during the nine months ended September 30, 2026. Net cash provided by financing activities for the nine months ended September 30, 2025 consisted of proceeds of $5,759. This amount primarily consists of (i) $5,577 of proceeds from bridge loans, (ii) $195 of proceeds from related party loans, (iii) $24 of payments of debt issuance costs associated with the bridge loans, and (iv) $11 of capital contributions.

 

Critical Accounting Policies and Estimates

 

There have been no material changes to our critical accounting policies and estimates from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, expenses, results of operations, liquidity, or capital resources.

 

Related Party Transactions

 

Refer to Note 3. “Related Party Transactions” of the Notes to our Financial Statements included elsewhere in this Form 10-Q for a discussion of related party transactions.

 

Recent Accounting Standards and Pronouncements

 

Refer to Note 2. “Summary of Significant Accounting Policies” of the Notes to our Financial Statements included elsewhere in this Form 10-Q for a discussion of recent accounting standards and pronouncements.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

(a) Evaluation of Disclosure Controls and Procedures

 

We conducted an evaluation, under the supervision and with the participation of our management, of the effectiveness of the design and operation of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2026, our disclosure controls and procedures were not effective because of certain material weaknesses in our internal control over financial reporting, as further described below.

 

26

 

 

(b) Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and disposition of the assets of our company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP and that receipts and expenditures of our company are being made only in accordance with authorization of management and directors of our company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

 

Management assesses the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in the 2013 Internal Control-Integrated Framework (or “COSO Framework”). As reported in our Form 10-K for the fiscal year ended December 31, 2025, management has concluded that we did not maintain effective internal control over financial reporting due to the existence of four material weaknesses, described further below. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We describe the material weaknesses in the following section.

 

(c) Material Weakness in Internal Controls Over Financial Reporting

 

We did not maintain effective internal controls over financial reporting, based on the criteria established in the COSO Framework, which resulted in deficiencies in principles associated with the control environment and its ongoing evaluation by management. These control deficiencies constituted material weaknesses, either individually or in the aggregate, relating to:

 

● The lack of sufficient Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”) control environment, including: (i) insufficient structured reporting to our Board of Directors and Audit Committee on the design and operating effectiveness of internal controls over financial reporting; (ii) the organization has not attracted, developed, or retained personnel with the competence required to design and execute SOX-compliant controls, including the competence to scope, review and challenge the work of the external accounting valuation and tax specialists on which it relies; (iii) organizational structures, reporting lines and authorities for the financial reporting function have not been formally defined, which is the structural driver of the segregation of duties condition; and (iv) no individual has been formally designated as accountable for our Sarbanes-Oxley compliance program.

 

● Following completion of our de-SPAC transaction we did not perform a formal assessment of the impact of this change on our internal control environment. As a result: (i) financial reporting objectives have not been defined in the context of public company obligations; (ii) risks to achieving those objectives have not been formally identified or assessed; (iii) no fraud risk assessment has been performed; (iv) accountability for the risk-assessment process has not been assigned; and (v) no evaluation was performed to assess the delta between our existing control environment and the requirements of an SEC registrant.

 

● Our failure to uplift our internal controls following our de-SPAC transaction. Specifically: (i) key controls lack documented evidence of review sufficient for audit purposes; (ii) data used in controls has not been validated for completeness and accuracy; (iii) third-party data is relied upon without evaluation of service organization controls or mapping of complementary user entity controls, and reliance on external specialists engaged for complex accounting, valuation and tax matters is not subject to structured internal review and challenge; (iv) no formal SOX policies or procedures have been documented; and (v) IT General Controls have not been scoped or evaluated.

 

● We do not have a monitoring program to assess whether internal controls over financial reporting are present and operating effectively on an ongoing basis.

 

These material weaknesses created a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 

These material weaknesses contributed to the omission of the operating expenses of our U.S. subsidiary, TerraUS, for April through June 2026 (approximately $800) from our interim consolidated financial statements for the three and six months ended June 30, 2026. These expenses were recorded in the three months ended September 30, 2026.

 

27

 

 

Management, with oversight from the Audit Committee, is implementing a plan to remediate the material weaknesses described above. As of the date of this Quarterly Report, we have:

 

● hired additional finance personnel to improve segregation of duties and oversight of outsourced service providers, and we continue to recruit. A chief financial officer for our U.S. subsidiary has accepted our offer and is expected to join in December 2026;

 

● transitioned our outsourced accounting support to a new provider, and we are defining the scope of its services and documenting management’s review of its work;

 

● completed Sarbanes-Oxley training for our control owners;

 

● completed an internal review of our financial reporting processes, including mapping key controls to identify where preparer and reviewer roles are not segregated, which will serve as the baseline for our control documentation;

 

● implemented interim manual processes, including additional reconciliations, tie-outs to source records and review, which will remain in place until our IT general controls have been remediated;

 

● added a review of the completeness of each subsidiary’s results, including trial balances obtained directly from each subsidiary, to our quarterly consolidation process; and

 

● resumed regular reporting to the Audit Committee on remediation progress, which will occur at least quarterly.

 

Our remaining remediation measures include:

 

● designating a Sarbanes-Oxley compliance program owner;

 

● documenting Sarbanes-Oxley policies, procedures and control templates, including a compensating controls assessment and a formal delegation of authority;

 

● performing a formal fraud risk assessment over financial reporting and reporting the results to the Audit Committee;

 

● implementing data validation protocols for control inputs;

 

● obtaining and reviewing SOC-1 reports for key third-party service providers and completing CUEC mapping;

 

● scoping and remediating our IT general controls, including user access and change management, with support from an IT audit specialist; and

 

● operating and testing the new and redesigned controls.

 

We expect to complete our remediation efforts during 2027. The material weaknesses will not be considered remediated until the applicable controls have operated for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

 

(d) Changes in Internal Control over Financial Reporting

 

There were no changes during the quarter ended September 30, 2026, in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

28

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

We are, and from time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of our management, if determined adversely to us, would individually or taken together have a material adverse effect on our business, financial condition or operating results.

 

Defending such proceedings is costly and can impose a significant burden on management and team members. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

 

ITEM 1A. RISK FACTORS.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

On September 22, 2026, the Company granted 200,000 restricted ordinary shares under its 2025 Equity Incentive Plan to three service providers which were registered pursuant to Registration Statement on Form S-8 filed on July 2, 2026.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

During the three months ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.

 

29

 

 

ITEM 6. EXHIBITS.

 

Exhibit No.

  Description
10.1   Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on September 22, 2026).
10.2   Employment Agreement between Terra Innovatum Corp. and Katherine Williams (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on August 27, 2026).
10.3   Directorship Agreement between Terra Innovatum Global N.V. and Katherine Williams (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed on August 27, 2026).
10.4*   Terra Innovatum Global N.V. 2025 Equity Incentive Plan
31.1*   Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*   Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because iXBRL tags are embedded within the Inline XBRL document).
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*   Cover page from the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2026 formatted in Inline XBRL (included in Exhibit 101).

 

* Filed herewith.
** Furnished herewith.

 

30

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 16, 2026 Terra Innovatum Global N.V.
   
  /s/ Alessandro Petruzzi
  Name: Alessandro Petruzzi
  Title: Chief Executive Officer
    (Principal Executive Officer)
   
  /s/ Katherine Williams
  Name: Katherine Williams
  Title: Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

31

 

Keep reading